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Cervical cancer is responsible for ~250,000 deaths per year worldwide, most of
which occur in developing countries. Virtually all cervical carcinomas test positive
for human papillomavirus (HPV) DNA, with about 60% of them positive for
HPV16. Two of the eight known genes encoded by HPV16, the early genes 6 (E6)
and 7 (E7) are responsible for cell-transformation and transition to malignancy.
The E6 protein binds to a cellular E3-ubiquitin ligase (E6AP) and this complex
targets p53, an important cellular apoptosis messenger, for degradation. E6 is
expressed throughout cancer progression, necessary for the survival of the cancer
cell even at late metastatic stages and thus makes for an excellent drug target. For a
rational approach to drug design a structure of sufficiently high resolution would
be necessary. However, even though the significance of the protein has been
understood for 14 years now, not only remains its three-dimensional structure
unsolved but there is scant understanding of fundamental biophysical properties of
the E6 protein. Here, I present an effective way to prepare large amounts of soluble
E6, a new method to stabilize monomeric E6 protein at high concentrations, and
insight into its multimerization behavior. Furthermore, to understand the inherent
flexibility of the protein, the interaction of E6 with a new cellular interaction
partner, CBP/p300, is discussed.
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2 - Introduction
2.1 Classification and history
The papillomaviruses (PVs) induce warts (or papillomas) in several higher
vertebrates, including man. Their family, the papillomaviridae, is grouped together
with the polyoma viruses and the simian vacuolating virus (SV40) to form the
papovavirus family. The properties shared by these viruses include small size, a
non-enveloped virion, an icosahedral capsid, a double-stranded circular DNA
genome and the nucleus as a site of multiplication. The papillomavirus particle has
a diameter of 55 nm, distinguishing it from the smaller polyoma virus particles
with a diameter of 45 nm.
Papillomaviruses are widespread in nature and have been characterized from
human, cattle, rabbits, horses, dogs, sheep, elk, deer, nonhuman primates, the
harvest mouse, the multimammate mouse and others including some avian species
(Sundberg, 1987). In general they are highly species specific and associated with
purely squamous epithelial proliferative lesions (warts) which can be cutaneous, or
can involve the mucosal squamous epithelium form the oral larynx, trachea,
pharynx or the genital tract. Most of the papillomaviruses have a specific cellular
tropism for squamous epithelia. The later, reproductive part of the viral cycle
seems to be limited to terminally differentiated squamous epithelial cells.
To date, over 100 different human papillomaviruses have been described. Since
serologic reagents are not generally available to distinguish each of these types,
they are not referred to as serotypes. Instead, they are classified as distinct types,
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according to their nucleotide sequence similarity with the dissimilarity of their L1
genes not allowed to exceed 90%.
Once a type status has been established the virus is named after its natural host and
assigned a number to reflect the temporal order of its characterization. Due to the
extreme host species specificity confusion is unlikely. Subtypes are designated by
an additional alphabet suffix e.g. HPV6b.
2.2 Cervical cancer
World-wide about 500,000 new cases of invasive cancer of the cervix are
diagnosed annually (Peto, 1986). In developing countries, cancer of the cervix is
the most frequent female malignancy and constitutes about 24% of all cancers in
women. In developed countries it ranks behind cancers of the breast, lung, uterus
and ovaries and accounts for 7% of all female cancers. The lifetime risk of dying
from cervical cancer may vary as much as tenfold among different countries
(Figure 1).
       
Figure 1: Prevalence of cancer related deaths in women for a typical country of the developed
world compared to the distribution in a neighboring, developing country. Source: WHO
regional statistics
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Nearly all cervical cancers originate in the ‘transformation zone’ which is located
at the lower end of the cervix where the columnar cells of the endocervix form a
junction with the stratified squamous epithelium of the vagina. Cells of the
transformation zone undergo a rapid turnover and appear to be particularly
vulnerable to the action of carcinogens. The high incidence of cervical cancer as
compared with the low incidence of cancer at other sites in the female lower
genital tract (vagina, vulva, perineum) is ascribed to changes of the differentiation
of cells across the transformation zone of the cervix, a process referred to as
“squamous metaplasia”.
Invasive cervical cancer is preceded by a progressive spectrum of abnormalities of
the cervical epithelium (Richart and Barron, 1969). These lesions are classified as
cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3. The severity of the lesion
is graded by the extent to which the normally differentiating, non-mitotic
suprabasal cells of the cervical epithelium are replaced by the non-differentiating
and mitotically active basal-like cells. In invasive cervical carcinoma the
abnormal, non-differentiating cells breach the basement membrane, invade the
stromal tissue, and eventually metastasize to lymph nodes and other sites in the
body. The time interval between early cervical abnormalities and invasive cervical
cancer may span several decades. During this long interval cytological
abnormalities can be detected by a pap-smear test and treated easily. The evidence
linking high-risk HPVs and squamous cell carcinoma of the cervix has been
derived from many studies suggesting that virtually all cervical carcinomas test
positive for high-risk HPV DNA with HPV16 being detected in about 60% of all
cases (Bosch et al., 1995; Eluf-Neto et al., 1994; Lorincz et al., 1992; Munoz et al.,
1994; Peng et al., 1991).
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2.3 Virion structure
The capsid of the papillomaviruses is non-enveloped and icosahedral in structure,
it consists of 72 capsomeres (Baker et al., 1991), which are either hexavalent or
pentavalent making contact with
six and five neighbors of the
corresponding type, respectively
(Figure 2). The capsid consists
of two structural proteins. The
major capsid protein (L1) has a
m o l e c u l a r  w e i g h t  o f
approximately 55kDa and
represents approximately 80%
of the total viral protein. A
minor protein (L2) has a
molecular weight of about 70kDa. Several groups have produced virus-like
particles (VLPs) by expressing L1 alone or a combination of L1 and L2
(Hagensee, Yaegashi, and Galloway, 1993; Kirnbauer et al., 1992; Rose et al.,
1993; Zhou et al., 1991). Although not required L2 is incorporated into VLPs
when coexpressed with L1 producing a particle that is in electron microscopy
nearly identical to particles consisting of L1 only. The L2 protein seems to be
partially necessary for the infection process, it makes contact with DNA and
directs the papillomavirus DNA to the intranuclear ND10 (nuclear domain 10)
particles for initiation of the viral life cycle (Florin et al., 2002a; Florin et al.,
Figure 2: EM picture of the capsid of human
papillomavirus. Courtesy of D.A. Galloway
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2002b; Okun et al., 2001). Complete papillomavirus particles contain a single
double stranded circular DNA genome of about 8kbp.
2.4 Genome organization
The circular HPV16 genome has eight ORFs, encoding six early genes (E1, E2,
E4, E5, E6 and E7) and two late genes (L1 and L2), and a long control region
(LCR) located between the L1 and E6 ORFs  (Figure 3).
        
Figure 3: Organization of the genome of HPV 16. Most of the ORFs overlap and the early
genes are all transcribed from a single promoter, P97, upstream of the E6 ORF.
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The size and location of the genes as well as the function of the proteins encoded
are well conserved among all PVs. The late genes encode two structural capsid
proteins L1 and L2 and are only expressed in the late viral cycle. The early genes
harbor all functions necessary for cell transformation, regulation of viral
transcription and viral replication. They are transcribed from one promoter, p97 (in
the case of HPV16) upstream of the E6 ORF that is regulated by a complex array
of multiple transcription factor binding sites in the LCR (Gloss, Chong, and
Bernard, 1989). Additionally, the pre-mRNA is spliced differentially depending on
the cell type and gives rise to a multitude of mRNAs (Doorbar et al., 1990;
Sherman et al., 1992; Smotkin and Wettstein, 1986).
2.5 The early proteins
2.5.1 The E1 protein
The papillomavirus E1 protein is largely involved in replication of the viral
genome. It has binding affinity to the origin of replication in conjunction with E2,
hydrolyzes ATP and has been shown to have ATP dependent helicase activity
(Bream, Ohmstede, and Phelps, 1993; Seo et al., 1993; Yang et al., 1993). E1 also
interacts with the p180 subunit of the cellular polymerase alpha primase and
presumably thereby recruits the cellular DNA-replication initiation machinery to
the viral origin of replication (Park et al., 1994).
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2.5.2 The E2 protein
Additionally to its function as an auxiliary factor for DNA replication E2 acts as a
transcription factor repressing expression of early genes from p97 at four distinct
E2 binding sites in the LCR (Smotkin and Wettstein, 1986; Thierry and Yaniv,
1987). Usually, once the viral genome is integrated into the host genome the
integration site lies within the E2 ORF, preventing its expression and lifting the
repression of p97 resulting in elevated E6 and E7 levels (Hwang et al., 1993;
Thierry and Yaniv, 1987)– often a prerequisite for malignancy. Traditionally, the
E2 protein has been described as a transcriptional activator, a function normally
studied in the bovine papillomavirus 1 (reviewed in  Hegde, 2002). Although the
HPV16 E2 protein has the same function, the search for an E2 binding site in the
HPV-16 genome with transcriptional activation function has remained fairly
enigmatic.
2.5.3 The E4 protein
The E4 protein does not appear to be essential for transformation or viral
replication (Hermonat and Howley, 1987; Neary, Horwitz, and DiMaio, 1987) and
has been associated with the collapse of the cytokeratin network (Doorbar et al.,
1991; Roberts et al., 1993) but it remains unclear what exactly the function of this
protein is.
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2.5.4 The E5 protein
The E5 protein has some transforming activity, several studies have shown that E5
can induce some transformed alterations in mouse cells (Leechanachai et al., 1992;
Leptak et al., 1991; Straight et al., 1993), increase the proliferation of human
keratinocytes (Storey et al., 1992) and stimulate cellular DNA synthesis (Straight
et al., 1993). The biochemical mechanisms by which E5 exerts its stimulatory
effects are still unclear. But apparently the E5 gene is not expressed in human
HPV-positive cancers indicating a role in benign papillomas or a role in initiating
the carcinogenic process only.
2.5.5 The E7 protein
The E7 protein encoded by HPV16 is a small, nuclear protein of 98 amino acids, it
is phosphorylated by casein kinase II (CKII) (Munger et al., 1992) and contains a
zinc binding domain of the C4 type (two CXXC motifs spanning an unusually
large loop of 29 amino acids) at its carboxy terminus (Barbosa, Lowy, and
Schiller, 1989; McIntyre et al., 1993) as illustrated in Figure 4. This portion of E7
can act as a multimerization domain (Clemens et al., 1995; McIntyre et al., 1993).
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The HPV E6 protein consists of two tandem copies of this domain and it has been
speculated that E6 and E7 may have evolved from a common ancestral precursor
(Cole and Danos, 1987). Initial insight into its functions came from the recognition
of functional similarities with the Adenovirus E1A protein (Phelps et al., 1988).
Like E1A, E7 can transform primary rodent cells in cooperation with the activated
ras oncogene (Matlashewski et al., 1987; Phelps et al., 1988), has some
transactivation activity (Phelps et al., 1988) and can induce DNA synthesis in
quiescent cells (Sato, Furuno, and Yoshiike, 1989). Functional similarities aside
E7 shares amino acid similarities with parts of E1A and the SV40 large T protein,
these shared regions bind cellular proteins, one of which is the product of the
retinoblastoma tumor suppressor gene pRB (DeCaprio et al., 1988; Dyson et al.,
1989; Whyte et al., 1988). E7 binds to pRB with a conserved LXCXE motif with
binding stabilized further by an adjacent stretch of glutamic acid residues.
Figure 4:  Primary Structure of the HPV16 E7 protein; the conserved regions 1 and
2 (CR I, CR II; similar to regions conserved in Adenovirus E1A or SV40 large T),
conserved region 3 (CR III), the pRB binding domain, the site for phosphorylation
by the casein kinase II and the location of the zinc binding domain are indicated.
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pRB is a member of a family of ‘pocket’ proteins which includes p107 and p130. It
acts as a regulatory subunit of complexes of the E2F family of transcription factor
controls (reviewed in Dyson, 1998) which regulate the transcription of important
cell-cycle factors. pRB is hypophosphorylated in G0 and G1 and phosphorylated
during S, G2 and M. Cyclin-dependent kinases phosphorylate Rb at the boundary
of G1/S and it remains phosphorylated until late M when a specific phosphatase
dephosphorylates it. Since Rb acts as a negative regulator of cell growth at the
G1/S boundary, it follows that the hypophosphorylated form represents the active
form with respect to its ability to inhibit cell-cycle progression.
The initial model was that E7, like SV40largeT and AdE1A, would
stoichiometrically interact with pRB and the other pocket proteins, thereby
displacing and aberrantly activating E2F. This activation of E2F would contribute
to cellular transformation. In support of this model, it was shown that mutations of
the LXCXE motif, interfering with pRB binding, reduce the cellular
transformation activity (reviewed in Phelps et al., 1992), and similarly that
enhancing the pRB binding efficiency of low-risk HPV6 E7 could increase its
transforming activity (Heck et al., 1992; Sang and Barbosa, 1992). But several
reports indicate that this model needs revision. E2F does not contain an LXCXE
motif and binds to a different region of pRB than E7 (Dick, Sailhamer, and Dyson,
2000; Huang et al., 1993; Wu et al., 1993). Additional sequences in the carboxy
terminal domain of E7 are required for disruption of E2F/pRB complexes (Helt
and Galloway, 2001; Huang et al., 1993; Wu et al., 1993). Some chimeras of
amino termini of E7 and carboxy termini of E6 were impaired for disruption of the
E2F/pRB complex but remained transformation competent (Braspenning et al.,
1998; Mavromatis et al., 1997). These results suggest that the ability of E7 to
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disrupt E2F/pRB complexes and cellular transformation are not necessarily linked.
Most strikingly the E7 of the cutaneous HPV1 can interact with pRB as efficiently
as HPV16 E7 and potently activates E2F responsive promoters, yet is
transformation negative (Ciccolini et al., 1994; Schmitt et al., 1994).
E7 induces degradation of pRB and the related pocket proteins (Berezutskaya et
al., 1997; Boyer, Wazer, and Band, 1996; Giarre et al., 2001; Gonzalez et al.,
2001; Helt and Galloway, 2001; Jones and Munger, 1997; Smith-McCune et al.,
1999). Inhibitors of the 26S proteasome interfere with E7 mediated pRB
degradation (Boyer, Wazer, and Band, 1996; Gonzalez et al., 2001). Since E7 can
interact with the S4 subunit of the 26S proteasome it might target pRB directly for
degradation via the proteasome (Berezutskaya and Bagchi, 1997), but an S4
binding deficient E7 mutant can still efficiently destabilize pRB (Gonzalez et al.,
2001), implying a different mechanism. Binding of E7 to pRB is necessary for
pRB degaradion, but additional sequences also contribute to E7 mediated pRB
degradation. HPV1 E7 for example, efficiently binds to but fails to destabilize pRB
(Giarre et al., 2001; Gonzalez et al., 2001).
The ability of E7 to catalyze the induction of proteolysis of pRB and the related
pocket proteins is a highly efficient strategy for a single E7 protein to inactivate
multiple molecules of cellular targets. The relatively low levels of E7 expressed in
HPV-infected lesions and transformed cells may necessitate this enzymatic mode
of action. In addition, this mechanisms ensures the abrogation of the whole
spectrum of pRB and pocket protein actions including those related to
differentiation and senescence independent of E2F (Sellers et al., 1998).
Furthermore, E7 subverts some functions of p53. Multiple mechanisms are
discussed to contribute to the interference of E7 with p53 induced G1 growth
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arrest, including E2F-mediated aberrant expression of the cyclins E and A
(Hickman, Picksley, and Vousden, 1994) and cdc25A (Katich, Zerfass-Thome, and
Hoffmann, 2001), inactivation of the p53-responsive CKI p21CIP1 (Funk et al.,
1997; Jones, Alani, and Munger, 1997), and the decreased steady-state levels of
pRB (Jones and Munger, 1997). Cells expressing E7 show increased levels of p53
(Demers, Halbert, and Galloway, 1994) and the normal degradation of p53
mediated by the cellular ubiquitin ligase MDM2 seems to be disturbed (Jones and
Munger, 1997; Seavey et al., 1999). Nonetheless, the rapid turnover of p53, a
prerequisite for cell immortalization, in HPV positive cells, expressing both, E7
and E6, is entirely due to one of the main functions of the E6 gene product, the
E6AP dependent targeting of p53 for ubiquitin dependent degradation via the 26S
proteasome.
2.5.6 The E6 protein
The E6 protein of HPV16 is a small polypeptide of 151 amino acids and contains
two putative zinc binding motifs (Barbosa, Lowy, and Schiller, 1989; Cole and
Danos, 1987), as illustrated in figure 5, which are crucial for all but a few of the
numerous different functions of E6 (Kanda et al., 1991; Sherman and Schlegel,
1996). The first pieces of evidence that E6 is a viral oncoprotein came from studies
on cervical tumors and derived cell lines, where E6 was found to be continuously
expressed even years after the original transformation event (Androphy et al.,
1987; Banks et al., 1987; Schwarz et al., 1985). Subsequently E6 was found to
possess transforming activity in a variety of assay systems. Although E6 alone has
only weak transforming activity it efficiently cooperates with the ras oncogene in
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the transformation of primary rodent cells (Liu et al., 1994; Pim et al., 1994;
Storey and Banks, 1993). Furthermore, E6 has immortalization capabilities for
primary human mammary epithelial cells (Wazer et al., 1995) although this
activity is also found with E6 of low risk HPVs (Band et al., 1993). Most relevant
for the evaluation of the transforming activity of all HPV oncoproteins is probably
the immortalization of primary human keratinocytes, which represent the natural
host cells of the virus. It has been demonstrated exhaustively that (high risk) E6
and E7 together are efficient at immortalizing primary human keratinocytes
(Hawley-Nelson et al., 1989; Munger et al., 1989). These immortalized cells will
not directly form tumors in nude mice. Only following expression of activated
oncogenes or extended numbers of passages in tissue culture will they become
fully transformed and tumorigenic (DiPaolo et al., 1989; Durst et al., 1989). This
nicely resembles the process of HPV induced tumorigenicity in vivo, where there
are long periods between the initial immortalization events and the ultimate
progression to cervical cancer, indicating the multiple steps of disease progression.
The individual expression of E6 or E7 in transgenic mice leads to epithelial
hyperplasia and skin tumors (Herber et al., 1996; Song et al., 2000), but E7 was
found to primarily cause benign, highly differentiated tumors, whereas those
promoted by E6 were mostly malignant. This suggests that the two oncoproteins
play different roles in the process of carcinogenesis, and also supports the idea that
they act cooperatively to induce transformation. Further investigation was
performed with E6 and E7 transgenic mice, following treatment with specific
carcinogens known to affect different stages of tumor progression. Here, E7 was
found to act strongly in tumor formation, whereas E6 contributed only moderately
to the early stages, acting more strongly during tumor progression, accelerating the
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malignant conversion of benign tumors (Song et al., 2000). This is of particular
interest since it suggests a pivotal role for E6 in malignant progression of HPV
induced tumors.
Among the more than twenty known interaction partners, the first to be described,
best understood, and probably most important one is still p53. The discovery of
this interaction shed the first light on the molecular mechanism of transforming
activity of HPVs and heralded in a new class of cellular proteins, the HECT-
domain E3 ubiquitin ligases, in the form of the E6 associated protein (E6AP).
   
The p53 tumor suppressor represents a major target for viral proteins since it can
promote cell cycle arrest or apoptosis of the infected cell once activated by the
unscheduled induction of DNA replication, necessary for viral replication, (el-
Deiry et al., 1993; Harper et al., 1993; Lowe et al., 1994; Wu and Levine, 1994).
To overcome this cellular safeguard several viruses encode proteins that
Figure 5: Schematic diagram of the HPV16 E6 protein. The regions identified as involved
in interaction with a few interaction partners, the c-terminal phosphorylation site and the
two zinc-binding domains are indicated.
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functionally inactivate p53. SV40LT prevents transactivation of p53 dependent
genes through association with its DNA binding domain (Ruppert and Stillman,
1993), AdE1B-55K abolishes the same function by binding to the transactivating
domain of p53 (Lin et al., 1994), but in cooperation with E4orf6 it can lead to p53
degradation as well (Steegenga et al., 1998; Tauber and Dobner, 2001), while p53
is sequestered by the HBV X protein into the cytoplasm (Elmore et al., 1997). The
strategy employed by (high risk) HPV E6 to suppress p53 function is to degrade it
through the ubiquitin dependent proteasome pathway (Scheffner et al., 1990). As a
consequence, p53 levels are extremely low in cervical cancer cells (Matlashewski
et al., 1986), and p53-induced growth arrest and apoptosis in response to DNA
damage are abolished (Foster et al., 1994; Kessis et al., 1993). Under normal
growth conditions, in the absence of HPV, p53 is turned over by the ubiquitin
proteasome pathway with MDM2, a cellular E3 ubiquitin ligase, initiating the
progress towards degradation (Honda, Tanaka, and Yasuda, 1997). Under stress
conditions this pathway is abolished and p53 is stabilized and activated (Ashcroft
and Vousden, 1999). Recent experiments have indeed shown that in HPV positive
cancer cells the MDM2 is completely inactive, while p53 degradation depends
entirely on E6 (Hengstermann et al., 2001). E6 targets p53 for degradation with a
sequestered cellular E3 ubiquitin ligase, E6AP. E6AP is a member of the HECT
domain family of ubiquitin ligases, whose large and divergent N-terminal domains
mediate substrate interaction, while the transfer of ubiquitin molecules is catalyzed
by the conserved C-terminal HECT domain (Schwarz, Rosa, and Scheffner, 1998).
E6 binds to E6AP within its N-terminal substrate recognition domain (Huibregtse,
Scheffner, and Howley, 1993a), which occurs prior to binding to p53 (Lechner and
Laimins, 1994) thus re-directing the specificity of E6AP towards p53 (Huibregtse,
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Scheffner, and Howley, 1993b). Indeed, blocking the activity of E6AP increased
the level of p53 in HPV positive but not in HPV negative cells (Beer-Romero,
Glass, and Rolfe, 1997; Talis, Huibregtse, and Howley, 1998), confirming that
E6AP plays a crucial role in E6 dependent degradation of p53 in vivo but is not
involved in degradation of p53 in the absence of E6.
Even though targeting p53 for degradation is the major route by which E6
overcomes its effects, several reports indicate that E6 makes use of additional
pathways to abrogate p53’s growth suppressive activities. Apparently, E6
abrogates transactivation by p53 independently of degradation through binding its
C-terminal DNA binding domain (Lechner and Laimins, 1994). Additionally,
repression of p53-responsive promoters could be mediated through the interaction
of E6 with the transcriptional coactivators CBP/p300 (Patel et al., 1999;
Zimmermann et al., 1999), similarly to what has been reported for Ad E1A
(Somasundaram and El-Deiry, 1997). Finally, cytoplasmic sequestration of p53 is
another common strategy adopted by different viral proteins, such as Ad E1B 55K
(Konig, Roth, and Dobbelstein, 1999), HBV X protein (Elmore et al., 1997) and
HPV E6. It has been reported that in HPV-positive cancer cells, the nuclear
localization of p53 in response to DNA damage is blocked even if proteasome
degradation is inhibited (Mantovani and Banks, 1999). Cytoplasmic retention
might be due to masking p53’s nuclear localization signal by E6 binding to p53 C-
terminus, or to enhanced nuclear export of p53. The mechanism of enhanced
nuclear export is supported by the observation that drug-induced inhibition of
nuclear export in HPV-positive tumor cells results in accumulation of p53,
indicating that E6-mediated degradation of p53 is partially dependent on nuclear
export (Freedman and Levine, 1998).
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However, recent reports indicate that not all p53 is degraded in infected cells
(Mantovani and Banks, 1999) and that there could be a positive role of p53 in viral
replication, possibly using its 3’-5’ exonuclease activity to enhance the fidelity of
replication (Massimi et al., 1999).
It is clear that the E6-p53 interaction represents one of the key-events in E6
induced malignancy: continuous degradation of p53 can lead to the accumulation
of genetic mutations in the infected cell. It has been shown that a complete loss of
p53 leads to early tumor development (Donehower et al., 1992) and enhances the
malignant progression of chemically induced skin cancers in mice, which is
consistent with the observation that E6 cooperates with E7 to accelerate the
malignant conversion of tumors (Song et al., 2000). Additionally E6 has been
shown to induce chromosomal alterations in tissue culture including translocations
and aneuploidy (Reznikoff et al., 1994).
Even though the inactivation of p53 is an important aspect of E6 function
mutational studies indicate that E6, to reach its the full transforming potential,
needs to interact with other cellular proteins, as well (Nakagawa et al., 1995; Pim
et al., 1994). It is now clear that E6 is multifunctional and interacts with numerous
cellular targets. However, the importance of these interactions for the tumor
progression towards malignancy remains hotly discussed.
2.6 The E6 protein as a drug target
Cervical cancer is one of the few cancers that has an external etiological agent,
“high risk” HPVs, as a necessary factor. Surely enough, cervical cancer is a multi-
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factor event, but the infection with “high risk” HPVs and the expression of its early
genes are necessary (not sufficient) for cancer development and progression.
The E6 and E7 proteins are the only papillomavirus proteins constantly expressed
throughout cancer progression. Even in late metastatic stages both proteins are
present. Taking into account the mechanism of action for their most prominent
cellular targets - the catalytic degradation of p53 and pRB, respectively, their
presence is obviously necessary for the continuing survival of the cancer cell.
Since pRB and p53 are not mutated or permanently incapacitated otherwise but are
being continuously expressed and then degraded, a loss of the function of E6 or E7
would be catastrophic for the cancer cell. The presence of functional pRB and p53
in a late cancer cell would immediately arrest the cell-cycle and most likely initiate
apoptosis (Francis, Schmid, and Howley, 2000).
This continuous dependency of the cancer cell on E6 or E7 for survival, the lack of
a beneficial role for both and the lack of homologous cellular proteins make E6
and E7 excellent drug-targets.
An example of anti-HPV E6 and E7 drug development is a recent study targeting
the cysteines of the two zinc fingers of E6 with oxidizing agents rendering them
incapable of coordinating zinc and the protein useless to execute its transforming
functions (Beerheide et al., 2000). As far as we are informed, company based
attempts of targeting E6 or E7 with a large, randomized drug-screen have been
unsuccessful and are currently not in progress. Current efforts to cope with HPV
infections focus on vaccination with virus-like-particles (VLPs), assembled from
purified L1 protein (Koutsky et al., 2002). Still, since E6 and E7 promise leverage
on cervical cancer even in its late stages, where a vaccination might be ineffective,
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we decided to investigate the biophysical and some functional properties of E6
(including also some pilot experiments on the E7 protein).
Here I present a new way of preparing and stabilizing large amounts of
biologically active, pure, concentrated, monomeric E6, a prerequisite for structural
studies, and insight into the different modes of interaction of E6 with cellular
proteins based upon studies of a new interaction partner.
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3 - Results (part 1): Biophysical properties of E6 and E7
3.1 Biophysical properties of the E6 and E7 proteins: Previous
data and concept of this study.
To determine the biophysical properties of proteins and, ultimately, determine their
three-dimensional structure (a prerequisite for rational drug-design), one needs
native, pure, concentrated and homogenous protein. The two methods employed
routinely for determination of high-resolution structure are X-ray crystallography
and Nuclear Magnetic Resonance (NMR). Briefly, in X-ray crystallography a
beam of coherent, short-wavelength electromagnetic radiation is diffracted by a
single protein crystal. The interference pattern allows the calculation of an electron
density map. Then the protein structure can be modeled according to this map.
NMR exploits the magnetic properties of certain nuclei. The nuclei used most
commonly are 1H, 15N and 13C. For collection of an NMR spectrum, the protein
solution is placed in a strong magnetic field where the magnetic moments of the
NMR-active nuclei align with the external magnetic field. These nuclei have a
resonance frequency that solely depends on the strength of the magnetic field.
Each individual nucleus ‘perceives’ a slightly different magnetic field: the sum of
the surrounding, strong magnetic field of the spectrometer and the small, local
fields of other nuclei in the direct vicinity. This perceived magnetic field varies for
each (chemically different) nucleus and, consequently, so does its resonance
frequency. The resonance frequency can be measured and used to determine
simple structures. Obviously, proteins are not simple molecules. Of the cornucopia
3 – RESULTS (PART 1) 34
of NMR methods, I only wish to mention one useful for determination of protein
structure, Nuclear Overhauser Effect Spectrometry (NOESY). Briefly, this method
allows direct measurement of distances between nuclei, even those not covalently
linked. The results are expressed as ‘distances’ (‘distance constraints’) for
individual pairs of nuclei. With these constraints a structure can be build up step by
step.
Both methods require considerable skill, but ultimately the determination of the
structure is a matter of routine – however, the drawback for both methods is the
availability of protein suitable for analysis. The ‘advantage’ of measuring a liquid
sample in NMR (eliminating the potentially tedious crystallization step), is, in
practice, rather small, since protein suitable for NMR tends to crystallize readily
and proteins that cannot be crystallized tend to perform poorly in NMR.
While expression of recombinant E6 or E7 protein in a variety of host systems has
become routine, the over-expression of E6 and E7 frequently fails to yield soluble
and folded protein (Georgiou and Valax, 1996; Nomine et al., 2001b). Both
proteins are short polypeptides of only 151 (E6) and 98 (E7) amino acids,
respectively, and do not require any post–translational modification such as the
formation of disulfide bonds or glycosylation. Thus, they should have all the
information necessary for proper folding encoded in their primary structure, yet
they are difficult to prepare in suitable amounts, concentrations and quality for
biophysical measurements and 3D structure determination (Androphy et al., 1987;
Androphy, Schiller, and Lowy, 1985; Grossman, Mora, and Laimins, 1989).
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3.2 Biophysical properties of the E7 protein: Experimental data
The primary objective was to prepare E7 protein in amounts and quality suitable
for structural analysis. To facilitate high level of expression in E. coli, the entire E7
gene was reconstructed from ten oligonucleotides, using codons common in E.
coli. For easier purification, a hexahistidine tag was added at the carboxy terminus






CGATCTGCTCTCAGAAACCG). The expression level of the optimized E7
(E7eo, hereafter) in E. coli is increased compared with the expression of the
original E7 construct (lane 1 compared with lane 2 in Figure 6).
                             
Figure 6. Expression and metal-affinity purification of HPV16 E7eo.
Lane 1: cleared lysate of BL21 (DE3) transformed with pET22b(+) HPV16 E7; Lane 2:
cleared lysate of BL21 (DE3) transformed with pET22b(+) HPV16 E7eo; Lane 3:
Flowthrough of Ni(II) column; Lane 4: Washing with 40 mM imidazole; Lane 5-8: Elution
with 200 mM imidazole, fractions 1-4
3 – RESULTS (PART 1) 36
While Figure 6 shows the protein on a denaturing SDS-PA gel, the protein eluting
from the Ni(II)-column appears to be agglomerated and a mixture of complexes of
different sizes as shown in Figure 7. The size distribution under non-denaturing
conditions was assessed with two different size-exclusion columns of effective
separation ranges below 75 kDa (Superdex 75) and below 200 kDa (Superdex
200). The separation of the Superdex 200 column shows that the bulk of the
protein elutes at molecular masses above 66 kDa (mass of the largest protein-
standard used) and not around 12 kDa (calculated mass of E7eo: 11.8 kDa) where
a monomer of E7 should elute (Figure 7). The size-exclusion chromatograms
suggest that the bulk of the protein has multimerized unspecifically, since only one
resolved peak at around 40 kDa is observable whereas most of the protein elutes
over a wide range of high molecular masses.
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The E7 protein has seven cysteins, four coordinate a single zinc (II) ion. To check
whether any of those cysteins contribute to agglomeration by forming covalent
bonds between individual E7 molecules, the protein was run under reducing and
Figure 7: Determination of the size distribution of HPV16 E7.
A: Size-exclusion chromatography of HPV16 E7 after metal-affinity chromatography on a
Superdex 75 column. (The bars in the upper right corner indicate the elution volumes of the
molecular size markers (SIGMA, USA); starting from the left: bovine albumin, 66kDa;
carbonic anhydrase, 29kDa, cytochrome C, 12.9kDa and aprotinin, 6.5kDa.)
B: Size-exclusion chromatography of HPV16 E7 after metal-affinity chromatography on a
Superdex 200 column. (The black strokes in the upper right corner indicate the elution
volumes of the molecular size markers (SIGMA, USA); starting from the left: bovine
albumin, 66kDa; carbonic anhydrase, 29kDa and cytochrome C, 12.9kDa.)
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non-reducing conditions on SDS-PAGE (Figure 8). Clearly, there was no
indication of a covalently linked dimer or multimer.
                                        
The above results suggest that agglomeration occurs due to non-covalent
interactions. Most likely, individual E7 molecules would bind each other via
‘normal’ electrostatic interactions; – or, since E7 is a metal binding protein the
monomers could perhaps be linked to each other via metal-ions coordinated inter-
molecularly.
Figure 8: No covalently linked dimers or multimers of HPV16 E7. HPV16 E7
was purified by metal-affinity chromatography and run on SDS-PAGE under
reducing and non-reducing conditions, with and without heat-denaturaion. The
size relative to the size markers does not change dramatically.
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Figure 9: Influence of chelating
agents on the agglomeration of
E7. After metal-affinity
purification the protein was
treated overnight at 4 ˚C and
analyzed with a Superdex 200
gel-filtration column. The
buffers included:
A: no chelating agent,
B: 5 mM 1.10 phenanthroline,
C: 5 mM l-carnosine and
D: 5mM l-penicillamine
(The bars in the upper right
corner indicate the elution
volumes of the molecular size
markers (SIGMA, USA);
starting from the left: bovine
albumin, 66kDa; carbonic
anhydrase ,  29kDa and
cytochrome C, 12.9kDa.)
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It has been reported that metal-binding proteins can use metal-ions to link different
subunits of a larger complex (Frankel et al., 1988). If that was the case with the E7
protein, the presence of strong competitors for the zinc (II) ion bound by E7 should
influence the formation of agglomerates. As shown in figure 9, chelating agents do
influence the formation of large agglomerates of E7, albeit weakly. The E7 protein
seems to exist in at least two different forms, of about 40 kDa and of about 50 kDa
– which is unexpected considering the calculated molecular mass of 11.8 kDa.
It proved difficult to purify one of those forms and therefore I chose to denature
the protein early in purification and later renature it to determine which form of E7
is the most stable one. In the presence of 8M Urea (which is mildly chaotropic) the
protein elutes in a single peak at around 20 kDa (according to size standards under
denaturing conditions), which is remarkably close to the elution volume of the
fraction with the smallest apparent molecular mass of E7 (~40 kDa) under non-
denaturing conditions (data not shown). Once the denaturing agent is removed or
sufficiently diluted, E7 tends to agglomerate again, especially at increased
concentrations – but this appears to be pH dependent (Figure 10).
In mildly alkaline conditions the bulk of the protein has an apparent size of about
40 kDa, is soluble at concentrations of up to 0.7 mM (9 mg/mL) and stable for
days at RT.  Conversely, slightly acidic conditions agglomerate the protein.
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Figure 10: Agglomeration of
renatured E7 protein is pH
dependent. After renaturation
at different pHs and
following concentration the
size distribution was assessed






(The bars in the upper right
corner indicate the elution
volumes of the molecular size
markers (SIGMA, USA);
starting from the left: bovine
albumin, 66kDa; carbonic
a n h y d r a s e ,  2 9 k D a ,
cytochrome C, 12.9kDa and
aprotinin, 6.5kDa.)
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3.3 Biophysical properties of the E7 protein: Conclusion
The calculated molecular weight of the HPV16 E7 protein is 11.8 kDa, but even
under denaturing conditions on SDS-PAGE, the protein appars to have a mass of
about 18 kDa. Here, after expression and purification on a large scale,  native E7
elutes from a size exclusion column at a volume corresponding to a molecular
mass of about 40 kDa. Similar observations have been made in a study by D.C.
Heimbrook’s group; the protein was observed to elute at 20 kDa (an unstable
species), 40 kDa and 60 kDa, possibly indicating mono-, di- and trimeric protein
(Patrick et al., 1992). But since the apparent mass of a protein in size-exclusion
chromatography is not a function of the molecular mass but of the hydrodynamic
radius, proteins can elute from a size-exclusion column at a volume corresponding
to a higher molecular weight standard. This could be the case with E7, since the
protein eluted at the same volume irrespective of native or denaturing conditions.
No covalently linked dimers or trimers could be detected, chelating agents did not
produce protein of a different apparent size and I never observed E7 of an apparent
size smaller than around 40 kDa. This interpretation is not entirely supported by R.
Marmorstein’s group which performed sedimentation studies that suggested two or
four E7 molecules in complexes with one or two retinoblastoma proteins,
respectively (Clements et al., 2000).
We discussed this with our collaborators, Tad Holak’s NMR Group at the Max-
Planck-Institute of Biochemistry in Martinsried, Germany, and it was decided to
use the “40 kDa”-fraction of E7 for structural studies. In this form the protein is
soluble and stable for days at 300 K (27 ˚C) in a spectrometer. In 1- and 2-
dimensional NMR studies with unlabeled and uniformly 15N-labeled protein, it
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emerged that the protein by itself does not assume a rigid structure. This might be
a necessary feature of the E7 protein, since it, even though tiny, interacts with a
large number of cellular proteins.
Currently, our collaborators study the properties of a complex of pRb and E7, since
the interacting domains of E7 should assume a more rigid fold and thus be
tractable for structural studies.
3.4 Biophysical properties of the E6 protein: Previous reports and
considerations for this study.
With the experience and expertise gained from the work with E7 I started to work
on the E6 protein. While there are many publications dealing with interactions of
the E6 protein with cellular targets (see above), only sparse biophysical data have
been published. Specifically, the three-dimensional structure of the E6 protein has
not been solved. Previous studies suggest that E6 is more problematic than E7, and
even when soluble, it may remain mostly unfolded and aggregated. Even
expression in the presence of chaperones like GroEl, careful purification and
painstaking mutation of potentially problematic amino acids does not significantly
improve the behavior of E6 (Ristriani et al., 2000). It has been concluded,
accordingly, that not only solubility but rather monodispersity should be a criterion
for successful preparation of native E6 (Clements et al., 2000; Nomine et al.,
2001a; Nomine et al., 2001b; Ristriani et al., 2000).
Based on these findings and the experiences with E7, I aimed to assess the factors
influencing agglomeration of the E6 protein. Assuming that agglomerated or
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multimeric E6 protein does not have a biological function, I postulated that
agglomeration is a consequence of over-expression and purification. E6 has two
potential zinc-binding domains comprising of four cysteins each and no disulfide
bonds. Therefore I speculated that reducing conditions with additional zinc might
be favorable for the purification of functional E6 protein. Unfortunately, zinc (as
with other transition metals) is difficult to administer properly.
Most proteins use zinc to facilitate electron transfer or to introduce secondary
structure with stable non-covalent links. The potential of zinc is reflected in the
large number of zinc binding proteins as well as in the tight control the cell exerts
on zinc levels and its trafficking and delivery to the target proteins. Indeed, the
level of unbound zinc in the cytoplasm is vanishingly low (Outten and O'Halloran,
2001; Rae et al., 1999). Even though there is a lack of general understanding of
how the cell dispenses zinc it can be assumed that zinc is handled like other
transition metals are. Recent years have seen spectacular advances in
understanding of how copper, another transition metal frequently incorporated into
proteins, is delivered to its targets. Several soluble cytosolic proteins, referred to as
metallochaperones, have been found to be required for the delivery of copper ions
to their target proteins through direct protein-protein interactions. (O'Halloran and
Culotta, 2000). This intricate mechanism has been demonstrated for the copper-
zinc-superoxide dismutase and its metallochaperone (Lamb et al., 2000; Lamb et
al., 2001; Rosenzweig and O'Halloran, 2000). It is not known how the E6 protein
acquires the zinc vital for its function, whether from a sequestered cellular
metallochaperone or by other means.
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Here, I present evidence that proper administration of zinc is crucial for formation
of the E6 monomer by showing that a chelating agent stabilizes monodisperse E6
protein. Possibly by competing with E6 for zinc, the chelating agent mimics the
function of a metallochaperone in vitro. Furthermore, I show that a chelating agent
disperses agglomerated E6 and conclude that agglomeration occurs due to
uncontrolled zinc delivery during the folding of E6. The findings lead to a strategy
to obtain monomeric, active and stable E6 protein and may help to re-evaluate
preparation protocols for other metalloproteins.
3.5 Biophysical properties of the E6 protein: Experimental data
In order to achieve high expression levels of the HPV16 E6 protein in E.coli I
redesigned the entire E6 coding sequence with codons that are highly frequent in
E.coli. To ease purification and increase the solubility of the E6 protein I attached
a C-terminal hexahistidine tag and an N-terminal SE-tag (Zhou, Lugovskoy, and














TGAAACCCAGCTGCACCACCACCACCACCACTAG). This chimeric gene, S-
E6, was efficiently expressed in E.coli but I realized that the bulk of the protein
was insoluble at physiological pH. However, at a non-physiological pH of 10.5
(pH 9 was not sufficient), a substantial proportion of the overexpressed protein was
soluble (Figure 11).
 
At these conditions S-E6 could be purified without major obstacles resulting in
pure S-E6 after metal-affinity- and anionexchange- chromatography (Figure 12).
Figure 11: Solubility of S-E6 after expression in E.coli is pH dependent. Lane 1:
uncleared lysate at pH 9; Lane 2: uncleared Lysate at pH 10.5; Lane 3: cleared lysate
at pH 9; Lane 4: cleared Lysate at pH 10.5; the arrow indicates the position of S-E6
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A large proportion of this S-E6 preparation precipitated during dialysis against
buffer at pH 7.8. The protein in the supernatant eluted from a size-exclusion
column in two peaks, one at high molecular weight close to the void volume of the
column, indicating a multimer, and another peak at a volume similar to carbonic
anhydrase (molecular weight: 29kDa), indicating an S-E6 monomer (calculated
mass of S-E6: 25.4 kDa)  (Figure 13 A). However, S-E6 is not stable under these
conditions, it agglomerates further (Figure 13 B) and eventually precipitates
completely.
Figure 12: Purification of S-E6 expressed in E. coli. The molecular weight markers are
indicated on the left. The arrow indicates the position of the S-E6 protein. Lane 1: lysate
after sonication; Lane 2: supernatant after centrifugation; Lane 3: flowthrough of metal-
affinity column; Lane 4: eluate of metal-affinity column; Lane 5: eluate of
anionexchange column
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Zinc interferes with the binding of E6 to E6AP in a specific manner (figure 14) and
it has been reported that E6AP binds to monomeric E6 (Daniels et al., 1997).
Figure 13: Purified S-E6 (after anionexchange chromatography) was dialyzed and then analyzed
with size-exclusion chromatography. The dialysis buffer contained 20mM phosphate, pH 7.8,
250mM NaCl, 4mM DTT. A: immediately after dialysis B: after 4 hours (The black bars in the
upper right corner indicate the elution volumes of the molecular size markers (SIGMA, USA);
starting from the left: bovine albumin, 66kDa; carbonic anhydrase, 29kDa, cytochrome C,
12.9kDa and aprotinin, 6.5kDa.)
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Thus, I investigated the agglomeration of S-E6 at different concentrations of zinc
during dialysis. Concentrations of zinc above 1 mM precipitated S-E6
quantitatively (data not shown) - as they would most other proteins; at
concentrations this high zinc is coordinated even by the free electron pairs of the
amide-nitrogen in the protein backbone (Yang et al., 2000). However, a
concentration of 20µM yielded soluble but multimeric protein (Figure 15 B). I
concluded that zinc was necessary for the solubility of S-E6 protein, but was
probably coordinated indiscriminately, resulting in multimeric protein. To
overcome this I added a competitor for zinc during dialysis. Ideally, such a
competitor would be a sufficiently strong chelator to compete with artifactual, but
not native, coordination of zinc by S-E6, thus mimicking the behavior of the
copper metallochaperone mentioned above, in vitro.
Figure 14: Zinc interferes with binding of E6 to an E6AP peptide. Zinc, Calcium (not a
transition metal, negative control) or Cadmium (transition metal, same group, different
period compared to zinc, positive control) were added to lysates containing E6 as indicated.
Those lysates were then passed over an E6AP affinity column, the column was washed,
boiled in SDS-sample buffer and analyzed on SDS-PAGE.
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Figure 15: Differences in the proportion of multimeric to monomeric S-E6 after dialysis in the
presence of various chelating agents. Purified S-E6 (after anionexchange chromatography) was
dialyzed and analyzed with size-exclusion chromatography. The dialysis buffer contained 20mM
phosphate,pH 7.8, 250mM NaCl, 4mM DTT and – A: no chelating agent, no zinc; B: no chelating
agent, 20µM ZnCl2; C: 2mM 1,10 phenanthroline, 20µM ZnCl2; D: 2mM EDTA, 20µM ZnCl2; E:
2mM EGTA, 20µM ZnCl2; F : 2mM l-penicillamine, 20µM ZnCl2; G : 2mM l-carnosine, 20µM
ZnCl2. (The black strokes in the upper right corners indicate the elution volumes of the molecular
size markers (SIGMA, USA); starting from the left: bovine albumin, 66kDa; carbonic anhydrase,
29kDa, cytochrome C, 12.9kDa and aprotinin, 6.5kDa.)
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 I investigated the effects of some chelating agents (Horning, Blakemore, and
Trombley, 2000; Llobet, Domingo, and Corbella, 1988) on the  agglomeration of
S-E6 by size-exclusion chromatography after dialysis.
L-carnosine did not precipitate S-E6, but neither did it prevent multimerisation
(Figure 15 G); ethylene-diamine-tetraacetic acid (EDTA) and 1,10 phenanthroline
precipitated the protein almost completely (Figure 15 C & D); whereas EGTA and
l-penicillamine stabilized monomeric S-E6 to different extents (Figure 15 E & F).
Dialysis against a buffer containing EGTA yielded S-E6 largely in monomeric
state whether additional zinc was supplied or not. However, if zinc was not
supplied, S-E6 was not stable and precipitated more rapidly. The presence of
20µM ZnCl2, 2mM EGTA (or l-penicillamine) and 2mM DTT stabilized the
monomer (one to two days at 4°C) up to concentrations of 0.1 – 0.2mM.
Intrigued by the structurally related chelating agents EDTA and EGTA having
such different effects on the oligomerization of S-E6 I compared the chelating
strength of three agents, EDTA, EGTA and l-penicillamine indirectly in a
competition assay against the fluorescent indicator TSQ. As expected, EDTA
appears to chelate zinc about 10 times more effectively than EGTA, which seems
about 100 times stronger than l-penicillamine (Figure 16). A chelator of
intermediate strength, like EGTA, appears most efficient at stabilizing the
monomeric state of S-E6.
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I monitored the stoichiometry of zinc bound by S-E6 during purification and after
dialysis in the presence of chelating agents with the TSQ assay and, for monomeric
protein after dialysis, also by Inductively Coupled Plasma/Optical Emission
Spectroscopy (ICP/OES). Since S-E6 has two putative zinc-binding domains, a
stoichiometric ratio of 2:1 (Zn:S-E6) would be expected for biologically active
protein. Surprisingly, I found Zn:S-E6 ratios closer to 1:1 for monomeric protein
and about 2:1 for multimeric protein only (Table 1). For the case of the two
strongest chelating agents, EDTA and 1.10 phenanthroline, we could not detect
any zinc in the precipitated S-E6 (data not shown).
Figure 16: Competition for zinc by three different chelating agents. 100pmoles ZnCl2 were
added to a mixture of 100µM TSQ and the indicated concentrations of EDTA, EGTA or l-
penicillamine. The residual fluorescence of the TSQ-Zinc complex was measured at 465nm.
(filled circles) – EDTA; (hollow circles) – EGTA; (filled squares) – l-penicillamine
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S-E6 multimer S-E6 monomer
[Zn]:[S-E6] [Zn]:[S-E6] [Zn]:[S-E6] [Zn]:[S-E6]
1.8(±0.36):1” 0.9(±0.18):1” -zinc, -chelator
2.2(±0.24):1 n/a +zinc




1.9(±0.26):1 1(±0.15):1 +zinc, +l-penicillamine
1.8(±0.24):1 n/a +zinc, +l-carnosine
0.6(±0.08):1 0.5(±0.09):1
n/a* n/a*
+ z i n c ,  + 1 . 1 0
phenanthroline
I wondered if the monomer of S-E6 is the biologically active form – as reported for
one of the multiple functions of E6 (Daniels et al., 1997), or alternatively, a
‘multimeric’ complex of specifically interacting S-E6 monomers. To address this
question I performed a p53 degradation assay with multimeric and monomeric S-
E6 preparations. Figure 17 shows that the S-E6 monomer is markedly more active
than its multimeric counterpart in this assay.
Table 1: Stoichiometric ratios of zinc to S-E6 after individual steps of purification and dialysis
with different chelating agents. The amount of zinc bound by S-E6 was measured using the
TSQ-Assay. (“) – some of the protein precipitated during dialysis; (*) – all of the protein
precipitated during dialysis; (#) - additional determination of zinc content with ICP/OES; (n/a) –
no protein eluted from the size exclusion column at this volume.
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As I had studied the effect of chelating agents during dialysis of S-E6 from a high
pH to a physiological pH, I wondered what effect a chelating agent might have if
added after the protein had completely multimerized. To study this question I took
a preparation of completely multimeric S-E6 protein and added EGTA to a final
concentration of 2mM. Size-exclusion chromatography of the protein preparation
before and one hour after addition of EGTA showed that the majority of the
protein was monomeric after EGTA treatment (Figure 18).
Figure 17: Monomeric S-E6 is more active biologically compared to its multimeric form in
catalysis of p53 degradation.  35S-methionine labeled p53 was incubated with S-E6 eluting from
size-exclusion chromatography at volumes corresponding to the exclusion limit (multimeric S-E6)
(squares), ~29kDa (monomeric S-E6) (triangles) and buffer without S-E6 (circles).
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From this I conclude that the presence of the proper chelating agent not only
stabilizes the monomeric, biologically active form of S-E6 when present during
Figure 18: Agglomerated protein is destabilized by addition of a chelating agent. A: size-exclusion
chromatography of purified S-E6 protein after dialysis in the absence of a chelating agent and in
the presence of 20 µM ZnCl2; B: the same sample 1h after addition of 2mM EGTA (The black bars
in the upper right corner indicate the elution volumes of the molecular size markers (SIGMA,
USA), starting from the left: bovine albumin, 66kDa; carbonic anhydrase, 29kDa, cytochrome C,
12.9kDa and aprotinin, 6.5kDa).
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refolding but that an appropriate chelating agent promotes the formation of
monomeric S-E6 even after it had multimerized completely.
Importantly, this protocol for the preparation of S-E6 protein can be scaled up for
the preparation of quantities large enough for structural studies and the protein
obtained is stably monomeric for days at 4 ˚C (Figure 19). Typically, 5 L of
bacteria culture yielded 1mL of pure, stable, monomeric protein at a concentration
of 5 mg/mL (0.2 mM).
Figure 19: Medium-Scale preparation of S-E6. A: S-E6 separated on a Superdex 75 preparative column
after dialysis; B: the pooled fractions of monomeric S-E6 from (A) analyzed after 2 days at 4 ˚C. (The
black bars in the upper right corner indicate the elution volumes of the molecular size markers (SIGMA,
USA), starting from the left: bovine albumin, 66kDa; carbonic anhydrase, 29kDa and cytochrome C,
12.9kDa).
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3.6 Biophysical properties of the E6 protein: Discussion
There has been considerable interest in the E6 protein ever since it was found to be
an important transforming protein of HPV16, the main causative agent for cervical
cancer. However, the HPV16 E6 protein is notorious for its awkward biophysical
properties (Imai et al., 1989; Nomine et al., 2001a). Tags (GST, MBP, His6, FLAG
etc.) have routinely been used to increase the solubility or ease the purification of
E6 without impairing its function (Gardiol et al., 1999; Ristriani et al., 2000;
Scheffner et al., 1993; Zimmermann et al., 1999). I decided to tag the E6 protein
with six histidines and the protein G subdomain B1, which is soluble, does not
interact with its fusion partner and is small enough to allow structural studies with
NMR, while attached (Zhou, Lugovskoy, and Wagner, 2001). The resulting fusion
protein, S-E6, is more soluble than native E6 but appears unchanged otherwise.
Still, 14 of its amino acids are cysteines (the tags do not contribute here), of which
8 are highly conserved and constitute the two putative zinc binding domains, while
the remaining 6 cysteines are not conserved and might simply require reducing
conditions (Nomine et al., 2001a; Ristriani et al., 2000). Mutational studies
indicated that the cysteine residues of the zinc-binding motif are crucial for all but
a few biological functions (Kanda et al., 1991). It has been postulated that E6
exists as a dimer, mainly on anecdotal evidence obtained while purifying E6
protein. The biological relevance of a dimer or an even larger homo-oligomer
remained questionable and a study of the interaction with E6AP presented
evidence for the function of monomeric E6 in this mechanism (Daniels et al.,
1997). I postulated that oligomerization might be the root of the problematic
behavior of the S-E6 protein in vitro. This postulation was based on unsuccessful
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crosslinking experiments and on mass spectrometry, which yielded molecule peaks
of monomeric protein (excluding zinc) under denaturing conditions and no signal
under native conditions, presumably because of a complex size too large to
vaporize and ionize (data not shown). Since the S-E6 protein has two putative
zinc-binding domains and zinc itself agglomerates proteins, I investigated the
effects of zinc on the oligomerization of S-E6. I found that high concentrations of
zinc precipitate S-E6 and low concentrations agglomerate it. To keep the S-E6
protein monomeric and soluble, a molecule was needed that mimicked a
metallochaperone to deliver zinc ions more specifically to the zinc-binding
domains of S-E6. Since no metallochaperone has been identified to deliver zinc for
E6, we investigated the effect of different chelating agents on the multimerization
of my S-E6 fusion protein. Our findings suggest four different agglomeration
states for S-E6, depending on the chelating agent and therefore the amount of zinc
bound. (i) S-E6 devoid of any zinc due to the presence of a strong chelating agent
is insoluble and precipitated; (ii) S-E6 with one zinc ion per molecule, delivered
(competed for) with a chelating agent like EGTA (or, to a lesser extent l-
penicillamine) is soluble, biologically active and monomeric; (iii) S-E6 with two
zinc ions per molecule leads to protein multimerized in a large complex, and (iv)
S-E6 with a large excess of bound zinc is insoluble and precipitated. The
stoichiometry of 2:1 (Zn:S-E6) for preparations of agglomerated S-E6 might imply
specific zinc-binding, as two putative zinc-binding sites are conserved throughout
all HPVs. However, we did not find evidence for biological activity of an S-E6
multimer. A ratio of one zinc-ion per S-E6 monomer indicates that only one zinc-
binding site is occupied, in agreement with earlier mutational studies (Kanda et al.,
1991) but contradicted recently (Lipari et al., 2001). The affinity of the two zinc-
3 – RESULTS (PART 1) 59
binding sites might be sufficiently distinct that our chelating agents remove zinc
from one site but not the other. Since the stoichiometric ratio of 1:1 did not impair
the S-E6 dependent degradation of p53, but rather prevented S-E6 oligomerization,
one might consider that one of the zinc-binding sites coordinates zinc inbetween S-
E6 molecules. This might switch E6 between monomeric and multimeric forms
depending on the zinc concentration (as proposed for other proteins, see  Berg,
1990).
I am currently attempting to crystallize S-E6. Structural studies with NMR, by our
collaborators, were unsuccessful even though preparations of monomeric,
unlabeled and uniformly 15N-labeled S-E6 were stable and sufficiently soluble (up
to about 0.2 mM). Two-dimensional 1H-15N correlation spectra did not reveal any
folded domains, not even the supposedly rigid zinc-coordinating cysteines. And
yet the protein was biologically active. One explanation for this seemingly
paradoxical behavior would be that E6 on its own is ‘unfolded’ or rather flexible
enough to accommodate binding to a large number of different cellular proteins; a
single, rigid structure might not allow for such versatility. A group of related
structures for E6 composed of different sub-structures might allow specific, high
affinity interaction between a small protein and a large number of partners. Indeed,
by now the number of interaction partners for E6 exceeds two dozen, suggesting a
‘flexible’ structure of unbound E6. To further understand the nature of this
‘flexibility’ I was involved in the identification and characterization of new
interaction partners of E6, most notably CBP/p300 as described in the following
chapter.
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4 - Results (part 2): Biological properties of E6
The same flexibility that makes it difficult to solve the structure of E6 could be a
necessary property of E6 to allow it to interact with multiple interaction partners in
different scenarios. We investigated new interaction partners and characterized
their modes of interaction. The one presented here is CBP/p300 (Zimmermann et
al., 1999; Zimmermann et al., 2000). This project was in the hands of Holger
Zimmermann and my contribution was to map and characterize the domain of E6
that interacts with CBP/p300.
4.1 Interaction of E6 with CBP/p300: Previous publications and
considerations for this study
As outlined earlier, viruses have similar obstacles to overcome to ensure their
survival and proliferation. A central problem is that most often they infect
mitotically resting, quiescent cells but need an active DNA replication machinery
for the amplification of their own genome. The transforming proteins of the small
DNA tumor viruses, SV40, adenovirus, and HPV target a number of identical
cellular regulators whose functional abrogation is required for this purpose. Two
of the proteins targeted for this purpose are the retinoblastoma gene product (pRB)
and p53, both important inhibitors of cell cycle progression (Vousden, 1995) as
described above. The mechanism of p53 degradation involves an active targeting
by E6 for ubiquitin dependent proteolysis by the 26S proteasome (Huibregtse,
Scheffner, and Howley, 1991; Scheffner et al., 1990; Talis, Huibregtse, and
Howley, 1998). E6 achieves this by forming a complex with E6-associated protein
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(E6AP), a cellular protein that acts as an E3 ubiquitin ligase (Scheffner et al.,
1993). The ability to form an E6-E6AP-p53 complex appears to be limited to high-
risk E6 proteins (Huibregtse, Scheffner, and Howley, 1991; Werness, Levine, and
Howley, 1990).
P53 is a transcription factor that requires the cofactor CBP/p300.  While
adenovirus E1A, SV40 large T and HPV E6 proteins all target p53, targeting of the
transcriptional coactivator CBP/p300 had only been described for SV40 and
adenovirus (Arany et al., 1995; Eckner et al., 1996; Lundblad et al., 1995). Hence,
our group investigated whether the transforming papillomavirus proteins target
CBP/p300 in a similar manner.
Through the interaction with specific transcription factors, CBP/p300 regulates a
variety of signal-modulated events (Janknecht and Hunter, 1996a). The
mechanisms by which CBP/p300 activates gene expression include (i) the ability
to modify histones and nonhistone transcription factors through intrinsic or
associated acetyltransferase activity (Bannister and Kouzarides, 1996; Gu and
Roeder, 1997; Ogryzko et al., 1996; Yang et al., 1996) and (ii) bridging the gap
between DNA-bound transcription factors and components of the general
transcription machinery (Nakajima et al., 1997).
Increasing evidence suggests that there is also a role for CBP/p300 in the
inhibition of cell cycle progression and cellular differentiation (Giles, Peters, and
Breuning, 1998). This may explain, at least in part, why CBP/p300 is the target of
SV40 and Ad E1A proteins. Recently published data have also demonstrated that
CBP/p300 activates p53-dependent transcription (Avantaggiati et al., 1997; Gu,
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Shi, and Roeder, 1997; Lill et al., 1997; Somasundaram and El-Deiry, 1997). Thus,
part of the cell cycle-inhibitory properties of CBP/p300 may result from its
involvement in p53-regulated events. Indeed, one mechanism by which SV40 and
adenoviruses can abrogate p53 function is by targeting the p53 cofactor CBP/p300,
and at least for Ad E1A, it has been shown that CBP-binding-deficient mutants are
no longer capable of down-regulating p53-dependent transcription (Gu, Shi, and
Roeder, 1997; Lill et al., 1997; Somasundaram and El-Deiry, 1997).
Interestingly, the down-regulation of p53-dependent transcription in vivo is not
limited to SV40 TAg and Ad E1A but has also been demonstrated for high-risk
HPV E6 proteins (Mietz et al., 1992). However, before we instigated our study no
interaction with the transcriptional coactivator CBP/p300 had been described for
the HPV E6 oncoprotein. It could be argued that the ability of high-risk HPV E6
proteins to degrade p53 through the E6AP pathway might be sufficient to explain
the abrogation of p53 transcriptional activity. However, adenoviruses also possess
the capacity to degrade p53 via the E1B 55-kDa protein (Roth et al., 1998;
Steegenga et al., 1998) and yet still target p53 transcriptional properties through an
E1A-CBP/p300 interaction.
For both SV40 and adenoviruses, the targeting of CBP/p300 has been shown to be
a prerequisite for transformation (Eckner et al., 1996; Moran, 1993; Yaciuk et al.,
1991). In the light of this, and the ability of E6 to interact with multiple cellular
targets (Kubbutat and Vousden, 1998), we wondered whether the HPV16 E6
protein might also target the transcriptional coactivator CBP/p300.
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4.2 Interaction of E6 with CBP/p300: Experimental data
The results presented in this part of the thesis were obtained in cooperation with
Holger Zimmermann. Some parts of figures are included to explain the whole line
of research while figures I did not contribute to are mentioned in the text only.
To determine whether the HPV16 E6 protein could interact with CBP/p300, we
partially purified these transcriptional coactivators from HeLa nuclear extract and
then passed the fraction enriched for CBP/p300 over an E6 affinity column.
Western blot analysis using the monoclonal antibodies p300 Ab-1 (Figure 20 A)
and NM11 (data not shown) detected a specific interaction between CBP/p300 and
GST-HPV16 E6. No interaction was detected for the control GST column, even
though a greater amount of protein was used. Also shown in Figure 20 A is the
interaction between full-length nuclear CBP/p300 and GST-P/CAF and GST-YY1,
both of which have previously been shown to interact with CBP/p300 (Lee et al.,
1995; O'Connor et al., 1996; Yaciuk et al., 1991). These data provide the first
evidence that a papillomavirus oncoprotein can associate with the transcriptional
coactivator CBP/p300, although they do not provide information about the nature
of the interaction.
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Both Ad E1A and SV40 TAg bind the CBP II domain of CBP (residues 1621 to
1877; also referred to as the C/H3 domain), which represents a hot spot for
transcription factor interactions (Janknecht and Hunter, 1996b). We tested whether
HPV16 E6 was also able to bind to this region of CBP, using a micro-affinity
column containing GST-CBP (1621 to 1877). In Figure 20 C it can be seen that
radiolabelled IVT HPV16 E6 does indeed bind to the GST-CBP II domain but not
Figure 20: 16E6 interacts with the transcriptional coactivator CBP/p300. A*: Equal
amounts of partially purified full-length (FL) CBP/p300 from HeLa nuclear extract were
passed over GST, GST-16E6, GST-P/CAF, and GST-YY1 micro-affinity columns. After
SDS-PAGE and transfer to PVDF membranes, Western blot analysis detected the
presence of CBP/p300. The positions of the molecular weight markers are also indicated.
B: Comparison of the 16E6-CBP II interaction with known E1A-CBP II and 16E6-E6AP
interactions in GST micro-affinity column assays. C: GST micro-affinity columns were
used to detect the interaction of IVT radiolabelled 16E6 with GST-CBP II (residues
1621 to 1877). No interaction was detected for the control GST column or the GST-CBP I
(residues 461 to 662) column. * I did not contribute to this experiment
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to GST or to GST-CBP I (461 to 662), another region of CBP that binds multiple
cellular transcription factors (Janknecht and Hunter, 1996b).
To determine the E6 binding site within the CBP II domain, we used a number of
GST-CBP constructs in micro-affinity column assays with IVT radiolabelled full-
length HPV16 E6 protein (Figure 21 A). We were able to identify a 19-amino-acid
region of CBP (1808 to 1826) that was capable of binding full-length E6 (lane 7).
Deletion into this sequence abolished binding to the E6 protein (lane 8). It can be
seen from Figure 21 A that the 19-amino-acid sequence is virtually identical in
both CBP and p300, with only one conservative change present, and a comparable
level of conservation is also observed for CBP/p300 proteins from other species
that are not shown here.
Interestingly, we had recently demonstrated that this same 19-amino-acid sequence
of CBP (1808 to 1826), which we have termed a transcriptional adapter motif, or
TRAM, binds numerous cellular factors and is also targeted by the Ad E1A protein
(O'Connor et al., 1999).
4 – RESULTS (PART 2) 66
Figure 21: Identification of an HPV-16 E6 binding site on CBP/p300. A: GST-CBP fusion
constructs used in micro-affinity column experiments to define CBP sequences capable of
binding 16E6 are shown schematically. A 19-amino-acid sequence of CBP (residues 1808 to
1826; lane 7) and larger fragments containing this sequence are able to bind 16E6. Deletion
into these sequences abolishes E6 binding (lane 8). Also shown is an alignment of this 19-
residue binding site of CBP and the corresponding p300 sequence. Eighteen asterisks represent
the conservation of 18-amino-acid residues in that sequence, while + represents the single
conservative change. B: 16E6 and Ad E1A bind the same 19-amino-acid motif in CBP. The
interaction between 16E6 and GST-CBP (1765 to 1852) can be disrupted by the presence of a
peptide (pep) consisting of Ad E1A sequences previously shown to bind the CBP TRAM.
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Confirmation that HPV16 E6 and Ad E1A both bind the CBP TRAM is
demonstrated in Figure 21 B. An E1A peptide that can bind the CBP TRAM is
capable of inhibiting the HPV16 E6-CBP interaction, while a mutant version of the
E1A peptide that is incapable of binding the CBP TRAM (O'Connor et al., 1999)
lacks this capacity completely. To assess whether the domain identified on CBP is
the only site of interaction with E6 in the context of p300 we tested several
deletion mutants of p300 for their ability to bind E6 in vitro (Figure 22).
Apparently, E6 binds to a segment at the N-terminus, the C/H3 domain and, to a
lesser extent, to the C-terminus. How these extra binding sites contribute to the
mode of interaction remains unclear, though. For further experiments we used the
CBPII domain.
The initial idea to investigate a possible interaction of E6 with CBP/p300 came
from the realization that some N-terminal sequence of E6 appeared similar to the
recently identified transcriptional adapter motif (TRAM) sequence of E1A
(O'Connor et al., 1999).
Figure 22: Interactions of HPV16 E6 with the cellular protein p300. Schematic representation
of p300. Five GST–p300 subclones spanning the whole p300 protein are shown. The two
panels to the right show that only subclones 1, 4 and 5 of p300 bind HPV-16 E6. The lower
panel shows the Coomassie blue-stained SDS gel of GST and GST–p300 fusion proteins.
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It has been suggested that functional differences between the E6 and E7 proteins of
different HPV types represent a cardinal factor in their ability to transform cells
and are reflected by their classification as either high-risk or low-risk types
(Barbosa et al., 1991; Vousden, 1995; zur Hausen, 1991). In the case of other
DNA tumor virus proteins, such as the Ad E1A protein and the SV40 TAg,
interaction with the transcriptional coactivator CBP/p300 has been shown to be
absolutely required for their transforming capabilities (Eckner et al., 1996; Moran,
1993; Yaciuk et al., 1991). If CBP/p300 is considered an important target in the
transformation processes of other DNA tumor viruses, we postulated that an ability
to target CBP/p300 might also be an important factor in distinguishing E6 proteins
of high-risk from low-risk HPVs. Consequently, we compared the abilities the E6
proteins from two high-risk types (HPV16 and HPV18) to bind CBP with those
from two low-risk types (HPV6 and HPV11).
In fact, Figure 23 clearly demonstrates that only the GST-E6 proteins of the high-
risk types (HPV16 and HPV18) bind to IVT CBP II, while those of the low-risk
types (HPV6 and HPV11) fail to bind CBP. The reciprocity of this observation is
evident from the inability of IVT HPV11 E6 protein to bind to a GST-CBP affinity
column.
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Subsequently, we checked for the domain of E6 involved in interaction with
CBP/p300. Quite frequently it proves difficult to pinpoint the interaction domain
of E6. There are only a few cases, most notably hDLG, where it was possible to
precisely define the interaction domain of E6 (Kiyono et al., 1997; Lee, Weiss, and
Javier, 1997). It was possible to map the interaction with CBP/p300 to one of the
two putative zinc-binding domains of E6, but, unexpectedly, not to the one with
the TRAM-like sequence. Using deletion mutants of E6 fused to GST to assess the
interaction we ran into technical problems quickly. The shorter the pieces of E6
Figure 23: The E6-CBP/p300 interaction is specific for E6 proteins of high-risk HPVs.
Micro-affinity column experiments using either GST fusion or IVT E6 proteins demonstrate
that only E6 proteins from the high-risk HPV types 16 and 18, but not the low-risk HPV
types 6 and 11, are capable of interacting with CBP.
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got the more difficult it was to distinguish between interacting and non-interacting
fragments. To overcome this, we constructed chimeras of high-risk HPV16 and
low-risk HPV11 E6, since high-risk E6 does interact with CBP/p300 while low-
risk E6 does not. So, in parallel we checked HPV16 E6 with parts of its sequence
changed to the corresponding sequence of HPV11 E6 and HPV11 E6 partly
changed to HPV16 E6 for interaction with CBP (Figure 24). The substitution of
the entire C-terminal zinc finger, amino acids 107-135 of HPV16 E6, with the
sequence for HPV11 E6 abolishes binding to CBP completely (Figure 24 A). The
exchange of smaller parts of the C-terminal HPV16 E6 zinc-finger, amino acids
114-128 and 121-135 fails to abolish binding completely (Figure 24 B), suggesting
a larger or non-linear interaction domain. This is supported by the reciprocal
experiments of chimeric HPV11 E6 with amino acids 107-121 or 121-135
substituted with the respective HPV16 E6 sequence which both bind to CBP
(Figure 24 C).
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In the context of a GST fusion protein (E6 amino acids 100 to 142), the cysteine
residues (C103, C139, and C140) could be substituted with glycine residues
without affecting the ability to bind CBP (data not shown). This finding suggests
that specific sequences within the second zinc finger of E6 are involved in the
interaction with CBP and that, here, at least, an intact zinc finger structure is not
necessary. However, we have not tested these mutations in the context of full-
Figure 24: Mapping of the E6 domain interacting with CBP. A: IVT-CBPII interacts
with residues 107-135. Lane 1: Input (10 %); Lane 2: Marker; Lane 3: GST; Lane 4:
GST-16E6 WT; Lane 5: GST-16E6 (107-135/11E6) The lower panel shows the
Coomassie blue-stained SDS gel of GST and GST–E6 fusion proteins. B: Lane 1: Input
(10%); Lane 2: Marker; Lane 3: GST; Lane 4: GST-16E6 WT; Lane 5: GST-16E6 (114-
128/11E6); Lane 6: GST-16E6 (121-135/11E6) C: Lane 1: Input (10%); Lane 2:
Marker; Lane 3: GST; Lane 4: GST-11E6 WT; Lane 5: GST-16E6 WT; Lane 6: GST-
11E6 (107-121/16E6); Lane 7: GST-11E6 (121-135/16E6) D: Alignment of the
sequences of the C-terminal zinc-binding domains of HPV 6,11,16 and 18, the position
of the zinc-coordinating cysteins is indicated.
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length E6 proteins alone and therefore cannot rule out the possibility that an intact
zinc finger structure is necessary to present the E6 residues contacting CBP under
these conditions.
One of the main functions proposed for E6 proteins of high-risk HPVs is the
targeting of p53 in order to suppress apoptosis of the host cell (Howley et al.,
1991; Myers and Androphy, 1995; Vousden, 1995). In the last few years, many
lines of evidence have suggested that one way in which this might be achieved is
by stimulating the degradation of p53 through the ubiquitination pathway
(Scheffner et al., 1993; Scheffner et al., 1990). Evidence has been provided both in
vitro (Huibregtse, Scheffner, and Howley, 1991) and in vivo (Talis, Huibregtse,
and Howley, 1998) that this activity is dependent on the interaction of E6 with a
cellular factor termed E6AP which then acts as a ubiquitin ligase (Scheffner et al.,
1993). The ability of E6 proteins to interact with E6AP has been shown to be
limited to those of high-risk HPV types (Werness, Levine, and Howley, 1990). It
has also been reported previously that E6 proteins of high-risk but not low-risk
types are able to down-regulate p53 transcriptional activity (Mietz et al., 1992).
One explanation for these observations is that down-regulation of p53-dependent
transcription results from the E6AP-dependent degradation of p53.
Recently, it was also shown that p53-dependent transcription can be activated by
CBP/p300 and that this activation can be abrogated by wild-type E1A but not a
CBP-binding deficient mutant of E1A (Avantaggiati et al., 1997; Gu, Shi, and
Roeder, 1997; Lill et al., 1997; Somasundaram and El-Deiry, 1997). The results
presented here have demonstrated that, like E1A, E6 proteins of high-risk HPVs
can also target CBP/p300. We therefore examined whether the down-regulation of
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p53 transcriptional activity by E6 proteins could be achieved through the binding
of CBP/p300 in a manner analogous to E1A.
To answer this question, we required a HPV16 E6 mutant that was deficient in
targeting p53 for degradation through the E6AP pathway yet was still capable of
binding CBP/p300. We assessed a number of existing HPV16 E6 mutants before
finding one with the desired properties. The HPV16 E6 mutant L50G contains a
point mutation in the first zinc finger of the E6 protein and has previously been
shown to be p53 degradation deficient (Nakagawa et al., 1995). Figure 25 A
demonstrates that this mutant is still able to interact with CBP in binding assays.
However, when we tested this mutant for its ability to bind either E6AP or p53 in a
similar assay, we found that it was deficient in this capacity (Figure 25 B).
Furthermore, results in Figure 25 C confirm that this mutant, like the low-risk
HPV11 E6 protein, is unable to degrade p53 in standard in vitro and in vivo
degradation assays.
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Figure 25: The 16E6 mutant L50G binds CBP but is unable to interact with E6AP or p53 and
cannot degrade p53 in vitro or in vivo. A*: Schematic representation of the 16E6 mutant (mut)
L50G showing the position of the amino acid exchange in the first zinc finger (marked by +)
and the identified CBP binding domain within the second zinc finger (bold line). GST micro-
affinity column experiments using IVT 16E6 L50G protein demonstrate the ability of this
mutant to interact with GST-CBP. B: Similar in vitro micro-affinity column experiments show
that unlike the wild-type 16E6 protein but similar to 11E6, the 16E6 mutant L50G is unable to
interact with either GST-E6AP or GST-p53. The lower panels indicate the loading of GST,
GST-E6AP, and GST-p53 proteins on the micro-affinity columns. C: The upper panel shows
p53 degradation assays using IVT 35 S-labelled p53 mixed with various IVT E6 proteins. The
numbered columns indicate the levels of p53 protein after various incubation times
(0, 30, 90, and 180 min) at RT. The lower panel shows an in vivo degradation assay in which
cellular levels of p53 are detected by Western blot analysis after cotransfection of U2-OS cells
with p53 and 16E6 constructs. The numbers represent the incubation period (in minutes) in
media containing cycloheximide before harvesting of the cellular proteins. While the
transfection of wild-type 16E6 leads to an observed decrease in cellular p53 levels after
60 min, the 16E6 mutant L50G is abrogated in this capacity.
* I did not contribute to this experiment
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A series of experiments to assess the ability of the wild-type and L50G mutant
HPV16 E6 proteins to down-regulate p53-dependent transcription was done
entirely without my contribution. Briefly, U2-OS cells were transfected with the
p53-responsive CAT reporter PG13CAT or the control vector MG15CAT, which
contains mutated p53 binding sites. Cotransfected with PG13CAT were various
expression plasmids coding for E6 proteins or Ad5 12S E1A. It was observed that
the PG13CAT vector was stimulated by endogenous p53 in U2-OS cells in a
manner dependent on intact p53 binding sites. No effect on the level of
transcriptional activity obtained with PG13CAT was seen upon the introduction of
an expression vector containing full-length HPV-11 E6 sequences. By contrast, the
expression of wild-type HPV16 E6 protein results in a significant reduction in
p53-dependent transcription. Consistent with the earlier analysis of the CBP
binding domain within HPV16 E6, the N-terminal 84 amino acids, which do not
bind CBP, fail to repress p53 activity, while the C-terminal half of HPV16 E6,
which contains the CBP binding domain, can repress p53-dependent transcription,
albeit slightly less efficiently than the full-length protein. Significantly, the HPV16
E6 L50G mutant results in a similar level of transcriptional repression as wild-type
HPV16 E6. Thus, in this respect the HPV16 E6 L50G mutant does not behave like
a protein of a low-risk type but rather like wild-type HPV16 E6. These data are
consistent with the idea that by targeting CBP/p300, an E6 protein from a high-risk
type can repress p53 transcriptional activity. Furthermore, the use of the HPV16
E6 L50G mutant suggests that this ability is independent of E6AP-mediated
degradation (Figure 6 + 7 in Zimmermann et al., 1999).
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4.3 Interaction of E6 with CBP/p300: Discussion
Frequently, the cellular regulators targeted by SV40 and Adenoviruses are
similarly targeted by the high risk HPVs (Dyson et al., 1989; Werness, Levine, and
Howley, 1990). While both SV40 and adenovirus proteins have recently been
shown to bind to the transcriptional adapter CBP/p300, no such interaction had
been described for HPV oncoproteins. One possible explanation for this is that all
previously known HPV functions that mirror Ad E1A and SV40 TAg properties
have been found to be present in the HPV E7 protein. To date no interaction
between HPV E7 and CBP/p300 has been described. Moreover, the recent finding
that HPV E7 proteins bind to and abrogate the function of p21 Cip1 in a p53-
independent manner (Funk et al., 1997; Jones, Alani, and Munger, 1997) has
suggested that E7 might not need to affect p53 activation by targeting CBP/p300,
since it can directly affect the function of this important downstream inhibitor of
cell cycle progression.
We set about identifying whether the HPV E6 oncoprotein could interact with
CBP/p300 for three reasons. First, we believed that since CBP/p300 represented an
indispensable target for transformation by Ad E1A and SV40 TAg, it was likely
that at least one of the HPV oncoproteins would also target CBP/p300. Second,
both adenoviruses and SV40 abrogate p53 activity in more than one way: by
affecting p53 directly and also indirectly through an interaction with the
transcriptional cofactor CBP/p300. Third, since HPV E6 proteins of high-risk
types had previously been shown to down-regulate p53 transcriptional activity, we
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felt that they might also bring about this effect through the targeting of the
coactivator CBP/p300.
Here, for the first time, we have provided evidence that the E6 proteins of high-
risk HPVs can bind CBP/p300, thus demonstrating an Ad E1A and SV40 TAg-like
property for HPV E6. One reason why the E6-CBP/p300 interaction might not
have been previously detected is that unlike E1A, which demonstrates an
extremely high affinity for this transcriptional coactivator and binds multiple
domains, HPV16 E6 binds the CBP II domain with only moderate affinity.
Coupled with this is the fact that any attempts to analyze HPV E6-CBP/p300
interactions using IVT full-length CBP/p300 would, from our experience, have
failed to detect such an interaction. The inability of in vitro-expressed full-length
CBP/p300 to interact with proteins that bind only the CBP II domain is not limited
to E6. Similar observations are also seen for other proteins, such as c-Fos and YY1
(Zimmermann and O'Connor). We interpret these results to imply that access to
the CBP II domain, in the context of full-length CBP/p300, is probably dependent
on posttranslational modification. For example, access to the CBP II domain might
be dependent on phosphorylation, because CBP/p300 phosphorylation is a
dynamic process regulated in a cell cycle-dependent manner (Ait-Si-Ali et al.,
1998; Kitabayashi et al., 1995; Yaciuk et al., 1991). By partially purifying full-
length CBP/p300 from HeLa cell nuclear extract, we have been able to overcome
these obstacles and demonstrate the ability of HPV16 E6 to bind full-length
CBP/p300 as do other transcription factors that bind only the CBP II domain.
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The HPV16 E6 protein, although only 151 amino acids in length, has been shown
to have multiple properties and interact with a plethora of cellular proteins
(Kubbutat and Vousden, 1998; Myers and Androphy, 1995). In light of the results
presented here, we can now add the transcriptional coactivator CBP/p300 to the
group of interacting cellular proteins. One advantage of targeting an important
transcriptional coactivator such as CBP/p300 is that it may result in an ability to
control multiple signaling pathways. That is because, in addition to p53, CBP/p300
acts as a cofactor for many other cellular regulators. Such a strategy appears to
have been adopted by the Ad E1A protein (O'Connor et al., 1999) and could also
apply to high-risk HPV E6 proteins.
One important role of CBP/p300 in cell cycle inhibition is in the facilitation of
p53-dependent gene expression. Previous observations have indicated that p53
transcriptional activity can be abrogated by E6 proteins of high-risk HPVs (Mietz
et al., 1992). One potential mechanism to explain this would be the promotion of
p53 degradation through the E6-E6AP pathway. However, the results presented
here in Figure 25 (and in Figure 7 of Zimmermann et al., 1999) show that an
HPV16 mutant (L50G) that can bind CBP/p300 but fails to bind E6AP and
degrade p53 in vitro and in vivo is still capable of repressing p53 transcriptional
activity. This finding suggests that for this particular property the correlation is
with CBP/p300 binding and not with the promotion of p53 degradation through the
E6AP pathway. However, the previous analysis that demonstrated the inability of
the HPV16 E6 mutant L50G, in conjunction with HPV16 E7, to transform human
embryonic kidney cells (Nakagawa et al., 1995) suggests that E6AP-dependent
degradation of p53 is still likely to be a prerequisite for the induction of cellular
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transformation. We therefore propose that the E6 proteins of high-risk HPVs target
p53 in two ways. The first, which may be a more immediate response, is the
abrogation of p53 transcriptional activity by binding to the cofactor CBP/p300.
The second would consist of the removal of p53 protein through E6AP-dependent
degradation. Together, these complementary functions of E6 could facilitate the
effective elimination of cellular p53 activity. Support for such a proposal comes
from a number of previous studies that utilize HPV E6 mutants and demonstrate an
independence of different aspects of transcriptional regulation from the ability to
promote p53 degradation (Crook et al., 1994; Crook, Tidy, and Vousden, 1991;
Lechner et al., 1992; Thomas et al., 1995).
CBP/p300 has been shown to activate transcription by at least two mechanisms:
one involving acetylation of histone and non-histone proteins, and one involving
the bridging of DNA-bound transcription factors to components of the basal
transcription machinery. HPV E6 proteins could potentially abrogate both of these
mechanisms of activation by binding to the CBP II domain. Recent reports have
indicated that as a consequence of p53 acetylation, CBP/p300 can indirectly
increase the affinity of p53 for its cognate DNA binding sites (Gu and Roeder,
1997). If HPV E6 (as well as Ad E1A and SV40 TAg) prevented this acetylation
by interacting with CBP/p300, then the affinity of p53 for target promoters might
be reduced. This represents a distinct possibility, since a number of reports have
demonstrated that the presence of E6 proteins from high-risk HPVs significantly
reduces p53 DNA binding activity (Lechner and Laimins, 1994; Thomas, Massimi,
and Banks, 1996; Thomas et al., 1995). The CBP/p300-associated
acetyltransferase, P/CAF, also binds to the CBP II region and has been shown to
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be displaced by Ad E1A (Yang et al., 1996). P/CAF promotes cell cycle inhibition
and cellular differentiation processes through its acetyltransferase properties (Yang
et al., 1996). Thus, by binding to the CBP II domain, HPV E6 might also down-
regulate these pathways in addition to its effect on p53.
In summary, the results presented provide evidence that E6 proteins from high-risk
HPV types, which already degrade p53 by a catalytic interaction with the cellular
E3 ubiquitin ligase E6AP, possess an additional mechanism, targeting the
transcriptional co-activator CBP/p300, by which to down-regulate p53 activity.
This is further evidence that the E6 protein even though small in size harbors a
variety of functions. Two similar functions, the direct inactivation of p53 and the
targeting of p53’s function via the transcriptional coactivator CBP/p300 are
executed by two different proteins, E1A and E1B, in the adenovirus system (Arany
et al., 1995; Eckner et al., 1996; Lundblad et al., 1995). Both of these functions are
found, as reported here, in the repertoire of the HPV16 E6 protein, as well.
Possibly, their small genome size, about 8 kbp compared with about 35 kbp for
adenoviruses, forced the HPVs to incorporate both functions in one protein. Still,
the interaction with CBP is only one of about 30 interactions currently known. It is
difficult to imagine specific interaction domains for all these targets in such a
small protein. Perhaps, E6 solves this conundrum by assuming a flexible structure,




It would be thought that a tiny protein like HPV16 E6 could have the potential to
interact with a very limited number of partners only. However, a large number of
cellular interaction partners has been reported. The first and arguably most
important function described is the interaction with E6AP, which leads to the
catalytic degradation of p53 (Kukimoto et al., 1998; Scheffner et al., 1993;
Scheffner et al., 1990). Among the others are the calcium binding proteins E6BP
(Chen et al., 1995) and fibulin-1 (Du et al., 2002), the transcriptional co-activators
CBP/p300 (Patel et al., 1999; Zimmermann et al., 1999), and ADA3 (Kumar et al.,
2002), the transcription factors c-Myc (Gross-Mesilaty et al., 1998) and IRF3
(Ronco et al., 1998), replication factor hMCM7 (Kukimoto et al., 1998), DNA-
repair proteins MGMT10 (Srivenugopal and Ali-Osman, 2002) and XRCC1 (Iftner
et al., 2002), protein kinases PKN (Gao et al., 2000) and Tyk2 (Li et al., 1999),
Rap-GTPase activating protein E6TP1 (Gao et al., 1999), apoptotic protein Bak
(Thomas and Banks, 1998), tumor necrosis factor receptor TNF-R1 (Filippova et
al., 2002), clathrin adaptor complex AP-1 (Tong et al., 1998), focal adhesion
component paxillin (Tong and Howley, 1997; Vande Pol, Brown, and Turner,
1998) and members of the PDZ domain protein family such as hDLG (Kiyono et
al., 1997) hScrib (Nakagawa and Huibregtse, 2000) and MAGI-1 (Glaunsinger et
al., 2000).
Furthermore, the interaction with CBP/p300 suggests that E6 is not severely
restricted in its number of interaction partners. E6 degrades p53 efficiently,
directly via the E6AP interaction. On the other hand, it also interacts with
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CBP/p300 in order to downregulate p53 dependent transcription. The second
interaction would seem redundant, therefore weakly selected, but oddly E6 is able
to harbor this function, as well.
Another peculiarity of the E6 protein is that it seems to be difficult to map the
domains where E6 interacts with its cellular targets. Only two examples of a
defined interaction domain are known. Those two are hDLG, which binds to the
carboxy-terminal PDZ-domain binding motif of E6 (Kiyono et al., 1997), and
CBP/p300 which binds a stretch of amino acids in the putative carboxy-terminal
zinc-binding domain of E6, as demonstrated above (and in (Patel et al., 1999;
Zimmermann et al., 1999)). For most other interaction partners it has usually only
been shown that mutation of the absolutely conserved zinc-binding cysteines
abolishes the interaction. These findings might suggest that the E6 residues that
bind to a given protein are juxtaposed due to the tertiary rather than the primary
structure of the protein. If the interacting residues were scattered all over the
protein, it would be difficult to identify them.
A high-resolution structure would obviously help to understand the properties of
E6. However, the only structural data available are predictions based on
calculations, and results of circular dichroism (CD) studies of purified E6 protein.
These agree in predicting a secondary structure largely composed of alpha helices
(Nomine et al., 2003; Ullman et al., 1996). Since alpha helices are rather rigid,
proteins that consist mainly of them should be of a fairly defined structure; thus
stable, soluble and easy to crystallize and solve. But the E6 protein is quite
insoluble and agglomerates rapidly unless stabilized, which might indicate
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flexibility. The NMR spectra indicate a flexible structure, too, and not even the
zinc-coordinating cysteines can be identified (Holak, 2001). Admittedly, this might
be due to the innate limitation of NMR in solving alpha helical proteins. The
residues in alpha helices have a very similar magnetic environment which in turn
makes their resonance frequencies alike and hence difficult to distinguish and
assign.
So, E6 can bind about 30 interaction partners within 151 amino acids; distinct
interaction domains are difficult to identify; it behaves like a flexible protein; it
appears, in NMR, to be flexible indeed; but it consists mostly of alpha helices?
How can this be possible?
Could the protein have evolved to assume different structures under different
conditions to accommodate a large number of binding partners? Obviously, the
protein would need to be flexible then. Must ‘flexible’ mean entirely, randomly,
disordered? I think this rather unlikely and prefer to imagine the ‘flexible’
condition as a defined set of structures that are energetically close enough to allow
the protein to continually switch at physiological temperatures. At any given time
the protein would, even if biochemically homogenous, exist in an ensemble of
different structures which would thwart any attempt to determine ‘the’ structure.
The E6 protein is predicted to have relatively even spaced, short alpha helices
alternating with disordered stretches of random coil (Figure 26).
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It is conceivable that the helices would function as ‘building blocks’ or sub-
domains and assume different orientations depending on the interaction partner.
This conformational switching could enable the protein to display a large number
of interaction domains by combining a limited number of sub-domains (Figure 27).
Figure 26: Amino acid sequence of HPV16 E6 and secondary structure predicted according to
two different algorithms (McGuffin, Bryson, and Jones, 2000; Rost, 2001). *= The zinc
coordinating cysteins; h= alpha helix; e= beta sheet; “ “= random coil. Two schematic,
proportional representations of the secondary structure of E6.
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Interestingly, a possibly similar mode of interaction has been shown for the E7
protein (itself perhaps sharing a common ancestor with the E6 protein (Cole and
Danos, 1987)). The short LXCXE motif in the CRII region of E7 which is the
primary site of interaction with pRb (DeCaprio et al., 1988; Dyson et al., 1989;
Lee, Russo, and Pavletich, 1998; Whyte et al., 1988) is predicted to be coiled
randomly. Nonetheless, pRB needs to interact additionally with carboxy-terminal
residues of E7, which are predicted to be partially alpha helical, for full activity
(Huang et al., 1993).
Figure 27: Model of combinatorial binding modes of domains of E6
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This combinatorial approach to protein-protein interaction could resolve the
contradiction that E6 appears to be flexible but seems to consist of rigid sub-
domains. Finally, if E6 switches between different distinct structures, it might be
necessary to ‘lock’ it in one structure in order to crystallize it. Crystallizing it in
complex with an interaction partner might be one way of achieving this.
5.1 Concluding remarks
Papillomaviruses are the paradigm for virus-induced carcinogenesis in humans.
The carcinogenic potential derives from the oncoproteins E6 and E7, which both
have a characteristic, large zinc-binding domain. This thesis and my recent paper
(Degenkolbe et al., 2003) report the first preparation of these proteins in stable
monomeric form, and describe biochemical and biophysical properties of E6 and
E7 in these preparations. Preliminary NMR data suggest that E6 and E7 do not
have a defined conformation. Thus the proteins may be flexible. It is possible that
this flexibility evolved to allow interaction with multiple partners for proteins at
the upper limit of their size.
I have proposed models of likely structural properties of E6 and E7 that might help
to explain their multitude of functions. One example of these functions, the
interaction with CBP/p300, has been identified and studied by my colleague
Holger Zimmermann and myself.
Presently, we are continuing NMR studies of my E7 protein preparations in
collaboration with Tad Holak’s group at the Max-Planck Institute for Biochemistry
in Martinsried, Germany. The chances for a successful determination of the
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structure of the E7 protein have improved recently since our collaborators
managed to prepare pRB in quantities suitable for structural studies. The next
experiments will involve titrations of 15N-labeled E7 protein with unlabeled pRb
protein while monitoring the signals of the amide protons in 2-dimensional 15N-1H-
heteronuclear correlation spectrometry (HMQC). The signals of the amide protons
of the interacting residues should shift upon binding, allowing for their
identification and subsequent determination of their three-dimensional orientation.
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6 - Experimental Procedures
6.1 Bacterial culture
Most of the DNA techniques used today in laboratories require the handling of
bacterial culture. The most commonly used organisms in recombinant DNA work
are derivatives of Escherichia coli strain K-12.
6.1.1 Growth of bacteria in liquid or solid media
Under ideal conditions E. coli grows exponentially. It grows rapidly on minimal
medium that contains a carbon source such as glucose and salts which supply
nitrogen, phosphorus and traces of metals. As the density of the culture increases,
the rate of division decreases until the bacteria reach a concentration (saturation
density) at which they no longer divide but stay alive. Bacteria are grown from
single colonies to ensure that each cell in a population is descended from a single
founder cell. Antibiotics are added to the growth media to prevent cross
contamination with other strains. Genes encoding resistance to antibiotics are
carried on plasmids and cells that contain the vector are identified by their ability
to grow and form colonies in the presence of the antibiotic.
Reagents:
Ampicillin 100 mg/mL stock solution
50 mg/mL working solution








- Bacteria are streaked out on a LB plate (with the appropriate antibiotic
added) using an inoculation loop
- The plate is incubated at 37 ˚C over night or until colonies become
visible
- A single colony is transferred to a 15 mL tube containing 5 mL LB
medium, containing the appropriate concentration of the selection
antibiotic
- The culture is used for experiments after reaching the right cell density
or used to inoculate a larger liquid culture
The rate of growth of a bacterial culture can be monitored by reading the optical
density of the culture at a wavelength of 600 nm (1 OD600 ≈ 8x10
8 cells/mL)
To maintain the colonies for a few weeks on the agar media, the plates are sealed
with parafilm and stored inverted at 4˚C
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For long term storage Glycerol is added to a the liquid culture to a final
concentration of 25 % and a small aliquot frozen at –80˚C
6.1.2 Preparation of competent cells
Competent cells are used for many standard molecular biology applications. The
exposure of the E. coli cells to Rubidium ions renders the cells able to take up
DNA, make them ‘competent’.
Reagents:
RF1 100 mM RbCl2
50 mM MnCl2
.4H2O




adjust with 200 mM acetic acid to pH 5.8
sterilized by filtration





adjust with NaOH to pH 6.8
sterilized by filtration
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Protocol:
- A single colony of E. coli strain DH5a or any other appropriate strain is
picked off a freshly streaked LB agar plate and dispersed in 4 mL of LB
medium and incubated for 8 hours on a shaker at 37 ˚C
- The culture is transferred to a larger volume and grown over night
- The next morning the culture is diluted 1:10 and incubated at 37 ˚C with
moderate agitation until the cell density is 4-7 x 107 viable cells/mL
- The culture is collected into 50 mL polypropylene centrifuge tubes and
chilled on ice for 10-15 minutes
- The cells are pelleted by centrifugation at 750-1000 g for 15 minutes at 4
˚C; the supernatant is removed quantitatively
- The cells are resuspended by moderate vortexing in a volume of RF1 buffer
that is 1/3 of the original volume and incubated on ice for 20 minutes
- The cells are pelleted again by centrifugation
- The cells are resuspended in RF2 to 1/12.5 of the original volume and
incubated on ice for 15 minutes
- Aliquots of 300 µL are distributed into 0.5 mL micro centrifuge tubes,
flash-frozen in liquid nitrogen and stored at -80 ˚C
6.1.3 Transformation of competent cells
When plasmid DNA is mixed with cells it presumably adheres to them. The
membranes of chemically competent cells become permeable when undergoing a
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heat shock, allowing the adherent DNA to enter the cell. The cells are then grown
in nonselective medium to allow the synthesis of plasmid encoded antibiotic
resistance proteins, then plated on antibiotic-containing medium to select for
plasmid containing bacteria.
Protocol:
- The cells are removed from –80 ˚C and thawed on ice
- Aliquots of 100 ml are used for each transformation
- The DNA solution, 1 mg purified plasmid from plasmid purification or ≤
20 mL from a ligation reaction is added and mixed gently
- The tubes are incubated on ice for 10-30 minutes
- The cells are placed for 45 seconds in a 42 ˚C water bath (heat shock) and
then chilled on ice for 2 minutes
- 800 mL of LB medium is added and the cells are incubated at 37 ˚C for 1
hour before plated out on LB plates containing the appropriate antibiotic
6.2 DNA
All genetic information, with the exception of the genomes of certain virus
families, is stored on DNA. DNA is a polymer of 4 different subunits, the
nucleotides cytosin, guanin, thymin and adenin, and often found as a dimer of
double helical structure.
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6.2.1 Quantitation of DNA and RNA
To determine the concentration and purity of DNA solutions, the OD at 260 nm
and 280 nm was measured in a spectrophotometer. The absorption of 1 at OD260 is
equivalent to 50 mg/mL of double stranded DNA or 40 mg/mL of single stranded
RNA. The ratio of the readings at 260 nm and 280 nm (A260/A280) provides an
estimate of the purity of DNA or RNA with respect to contaminants that absorb
UV light, such as proteins.
6.2.2 DNA amplification and purification
Polymerase Chain Reaction (PCR) is an in vitro method for enzymatically
synthesizing and amplifying defined sequences of DNA. The reaction uses two
oligonucleotide primers that hybridize to opposite strands and flank the target
DNA sequence that is to be amplified. The elongation of the primers is catalyzed
by a heat-stable DNA polymerase (such as Taq DNA polymerase) (Saiki et al.,
1985). A repetitive series of cycles involving template denaturation, primer
annealing and extension of the annealed primers by the polymerase results in
exponential accumulation of a specific DNA fragment. The ends of the fragment
are defined by the 5’ ends of the primers (Mullis et al., 1986; Scharf, Horn, and
Erlich, 1986). Because the primer extension products synthesized in a given cycle
can serve as a template in the next cycle, the number of DNA copies grows
exponentially.
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Reagents:
3M Na-Acetate pH is adjusted with 3M Acetic Acid to pH 5.2
dNTP mix 25 mM of each dNTP
50x TAE buffer 242 g Tris base
57.1 mL glacial acetic acid
37.2 g Na2EDTA
.H2O
add ddH2O to 1 liter
TE buffer 10 mM Tris-HCl pH 7.4
1 mM EDTA pH 8.0
Agarose gel solution 0.8-1.5 % agarose in 1x TAE-buffer
1 mg/mL ethidium bromide
Expand High Fidelity PCR System Roche Diagnostics GmbH, Germany
GFXTM PCR
Qiaquick Gel-extraction kit Qiagen, Hilden, Germany
Thermocycler Biometra® UNO II; Biometra, Germany
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Protocol:
- 100 ng of template are mixed in a thin wall PCR tube with:
5 mL of 10x reaction buffer, containing MgSO4
1 mL dNTP mix (final concentration of 500 mM for each dNTP)
100 picomoles 5’ primer
100 picomoles 3’ primer
top up with ddH2O to 49.5 ml
add 0.5 mL Taq polymerase
- The samples are placed in a thermal cycler
- Standard thermal profiled used:
Initial denaturation: 94 ˚C for 5 min
Denaturation: 94 ˚C for 1 min
Annealing: 60 ˚C for 1.5 min 25-30 cycles
Elongation: 72 ˚C for 1.5 min
Final Elongation: 72 ˚C for 10 min




20 mL 3M Na-Acetate
- The PCR product is pelleted in a micro centrifuge tube at 16000g for 15
min and the supernatant discarded
- The pellet is washed once with 70 % Ethanol centrifuged at 16000g for 15
minutes and the supernatant discarded
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- The pellet is briefly air dried and redisolved in an appropriate amount of
TE-buffer
- The PCR product is then purified according to their size on 0.8-1.5% (w/v)
agarose gels in a horizontal gel eletrophoresis chamber (Hoefer) until
optimal separation is achieved.
- Subsequently the DNA fragments are visualized on a Transluminator 4000
UV-screen (Stratagene, USA) at 312 or 254 nm
- To purify the DNA from an agarose slice, the DNA fragment is cut out
using a scalpel and transferred to a micro centrifuge tube
- 300 mL of buffer QX (from the Qiagen gel extraction kit) is added, mixed
and incubated at 56 ˚C until the agarose is dissolved completely
- The sample is transferred to the spin column and incubated at RT for 1 min,
then centrifuged at 16000g for 1 minute
- The flow-through is discarded, 500 mL of buffer PE are loaded on the
column and centrifuged at 16000g for 1 minute
- 20-50 mL of TE buffer is applied to the column and the sample incubated at
RT for 3 min
- The DNA is recovered by centrifugation at 16000g for 1 min
6.2.3 Gene assembly
Sometimes the expression of recombinant genes seems to be hampered by the
extensive use of codons rare in the host species. In E. coli for instance, the rarest of
the four codons for proline, CCC, is used in only five percent of the cases. The
same codon is the most common one for proline in Homo sapiens and occurs 20
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percent of the time (http://www.kazusa.or.jp/codon/). To avoid depletion of rare
tRNAs during high level expression it can be useful to redesign an entire gene with
a codon bias more appropriate for the designated host system. Here, the genes were
assembled from overlapping oligonucleotides in a touch-down-PCR-like reaction.
Reagents:
pfu polymerase + buffer Stratagene, USA
dNTP mix 50 mM of each dNTP
Protocol:
- mixture: 5 µL 10 x PCR Buffer
1 µg Primer 1 (5’ –primer)
1 µg Primer X (3’-most primer)
0.1 µg Primer 2 – Primer X-1, each
1 unit pfu polymerase
1 µL dNTP-Mix (200 mM solution)
final volume 50 µL
- The samples are placed in a thermocycler
- Temperature program:
ß 95 °C  4 minutes
ß 95 °C  1 minute
ß 62 °C  1 minute   (-0.5° / cycle)              12 cycles
ß 70 °C  1 minute
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ß 95 °C  1 minute
ß 55 °C  1 minute      28 cycles
ß 70 °C  1 minute
ß  4 °C   --
- Precipitation
- The resulting fragments are separated on an agarose gel, cloned into
the desired expression vector and sequenced.
6.2.4 Cloning of DNA fragments
In DNA cloning, a DNA fragment that contains a gene of interest is inserted into
the purified DNA genome of a self-replicating genetic element, either a virus or a
plasmid. The resulting recombinant DNA molecule can then be introduced into a
bacterial cell. The DNA fragment can be amplified in the bacterial host and later
isolated by plasmid preparation. The DNA fragments in this work were either
obtained by PCR of existing plasmids or genomic DNA or assembled in a PCR-
like reaction from overlapping oligonucleotides and then cloned into new
expression vectors.
6.2.4.1 Separation of DNA fragments with agarose gels
Agarose gels are used as a quick and effective way to separate DNA fragments
according to their size. This can be useful for qualitative assessment of a mixture
of DNA fragments or for purification. The DNA is visualized with ethidium
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bromide, an agent that once it has intercalated into DNA, fluoresces brightly under
UV-light. The DNA can easily be excised from the gel and extracted using a gel-





Ethidium bromide stock solution
Protocol:
- Prepare TAE buffer with 1 % Agarose
- Boil in a microwave oven until the agarose has melted completely
- Add 1 µL of ethidium bromide stock solution per 100 mL gel
- Swirl and pour into a suitable tray
- Once the gel has set put it into a gel tank with TAE buffer
- Load the samples and apply an electric field
6.2.4.2 Restriction digest
DNA fragments are digested with restriction enzymes to either excise a smaller
fragment from a larger one or to create overhangs for later insertion into a specific
site.
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Reagents:
10 x buffer (supplied with the enzyme)
restriction enzyme
Protocol:
- mix the DNA solution with buffer and enzyme(s)
- incubate at 37°C for 1 hour
6.2.4.3 Ligation
To connect fragments of DNA, like a newly assembled gene and a digested
expression vector, covalently again, a bacteriophage enzyme, usually the T4
Ligase, is used. It requires phoshorylated overhangs, ATP and can ligate ‘blunt’-
(no overhang) as well as ‘sticky’-ended (overlapping overhangs) DNA fragments.
The reaction is usually carried out at temperatures between 16°C and RT. The
resulting product can be transformed into bacteria directly.
6.2.4 Preparation of plasmid DNA
The principles of the method used here to isolate and purify plasmid DNA is based
on alkaline lysis of the cell, followed by binding of the plasmid DNA to an Anion-
Exchange resin under appropriate low salt and pH conditions. Proteins and other
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impurities are removed by a medium salt wash. The plasmid DNA is then eluted in
a high salt buffer and concentrated and desalted by isopropanol precipitation. The
quality of the obtained plasmid DNA is high enough for transformation and
sequencing. Plasmid DNA is isolated with the Qiagen or Macherey-Nagel plasmid
purification kit. The volumes written in the protocol described here are for using
the maxipreparation kit and have to be adjusted to the manufactures
recommendations when using different preparations.
Reagents:
TE buffer 10 mM Tris-HCl pH 7.4
1 mM EDTA pH 8.0
all other solutions are provided in the respective kits
QIAGEN® Plasmid Kit QIAGEN GmbH, Germany
NucleoBond® Kit Macherey-Nagel GmbH, Germany
Protocol:
- 400 mL of bacterial culture of E.coli harboring the plasmid of
interest is grown over night with constant agitation at 37 ˚C in LB-
medium containing the appropriate antibiotic
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- The bacterial culture is harvested by centrifugation at 6000g for 15
min
- The bacterial pellet is resuspended in 10 mL re-suspension solution
- 10 mL of lysis buffer are added, the suspension gently mixed and
incubated for 5 min at RT
- 10 mL of chilled neutralization buffer is added, the suspension is
mixed again and incubated for 20 min on ice
- The bacterial lysate is centrifuged at ≥20000g for 30 min at 4 ˚C
and the supernatant, containing the plasmid, is transferred to a new
centrifugation tube
- Centrifugation is repeated at ≥20000g for 15 min at 4 ˚C
- The supernatant is applied on an equilibrated resin column and
allowed to enter by gravity flow
- The column is washed twice with wash solution to remove all
contaminants
- The DNA is eluted with a high salt buffer and precipitated by
adding isopropanol (0.7 of the volume), mixed and centrifuged at
≥15000g for 30 min at 4 ˚C
- The supernatant is carefully discarded and the pellet washed with
70% ethanol and centrifuged at ≥15000g for 15 min at 4 ˚C
- The pellet is air dried for 15 min and re-dissolved in a suitable
volume of TE-buffer
- The yield is determined by UV-spectrophotometry and the purity is
determined on an agarose gel
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6.2.5 Site-directed mutagenesis
Quite often it is necessary to mutate individual bases of existing constructs. To
achieve this, two oligonucleotides (sense and anti-sense strand) harboring the
desired mutation and at least 20 bases of matching flanking sequence are designed.
To facilitate easy screening for successful mutation it is useful to incorporate
another, silent, mutation to create or destroy a restriction enzyme cleavage site.
The main criterion for successful mutagenesis seemed to be the melting
temperature of the oligonucleotides to their mismatched template. It can be
calculated with the following equation:
Tm, mismatch= 81.5 + (0.41*GC%) – 675/n – (% mismatched bases)
    (Stratagene, USA)
n= length of oligonucleotide
The melting temperature should be at least two degrees Celsius above the
extension temperature. During the reaction the target, a plasmid, is denatured, the
oligonucleotides are then annealed to the target, and extended until the polymerase
reaches the 5’ end of the oligonucleotides. This is performed several times with
both, sense and anti-sense strand resulting in a mixture of original, hemi-mutated
and fully mutated plasmids. The original and hemi-mutated plasmids are digested
with DpnI, a methylation dependent restriction enzyme, and transformed into
bacteria.
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Reagents:
VENT® polymerase Stratagene, USA
VENT® buffer
dNTPs 50 mM of each dNTP
DpnI NEB, USA
Protocol:
- 20 – 200 ng of template are mixed with 120 ng of each of the
mutated oligonucleotides, 1 unit of polymerase, buffer, water and 2
µL of dNTPs to a final volume of 50 µL
- Temperature program:
ß 95 °C  4 minutes
ß 95 °C  1 minute
ß 55 °C  1 minute                   14 cycles
ß 68 °C  2 minutes per kbp of template
ß  4 °C   --
- Addition of 1 µL of DpnI
- Incubation at 37 ˚C for 90 minutes
- Precipitation with:
ß 150 µL H2O
ß 20 µL 3M NaAc pH 5.5
ß 660 µL Ethanol
- Transformation into bacteria
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6.3 Protein
6.3.1 Expression of recombinant protein
The advantage of protein expression using derivative strains of E.coli is the ease
and speed of growing large cultures. Usually the bacteria are transformed with an
expression vector harboring the gene of interest downstream of a strong promoter
under the control of a regulating element. Here the regulator of expression was
derived from the commonly used lac-operon, which is induced permanently with
non-hydrolysable IPTG, and combined with the promoter of the bacteriophage T7
RNA polymerase. Obviously, only bacterial strains expressing the T7 RNA
polymerase can be used for expression, these strains usually have the gene
incorporated in their genome under the control of the same lac-operon. As a result
the control of expression is more stringent and the level of expression in non-
induced bacteria is low. For expression of proteins compromising the bacterial
health the background level of expression can be reduced even further by addition
of 1 % Glucose to the bacterial growth medium. Typically, bacteria were grown in
small overnight cultures and then diluted and grown until they were in exponential
growth phase. Once reached, the expression of the protein of interest was induced
with IPTG and the bacteria harvested after incubation at reduced temperature.
Reagents:
LB-Medium





- Transformation of E. coli ER2566 with expression vector for
protein to be expressed
- Overnight culture, 20 mL of LB-medium with 1 % Glucose and 100
ng/mL Ampicillin
- Dilution with 800 mL of LB-medium with 100 ng/L Ampicillin
- Growth at 37 °C until OD600 reaches ~0.5 AU
- Induction with 0.5 mM IPTG and shift to 30 °C
- Incubation for 4 hours
- Centrifugation at 4000g
- Storage of bacterial pellets at –80 °C
6.3.2 Uniform labeling of protein
Often it is necessary to label protein to ease the determination of the three
dimensional structure. The kind of label is determined by the method of structural
analysis. In this case, since NMR was the method of choice I labeled the protein
uniformly with the stable 15N isotope.
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Reagents:
Minimal medium for uniform 15N label (modified M15 medium):
Trace Solution 1.3 mL/L
Citric acid (tri-sodiumsalt) 1 g/L
Ferrum citrate 36 mg/L





adjust the pH to 7.4 with KOH and autoclave
MgSO4 10 mM (sterile filtered)









Citric acid monohydrate 5.5 g/L
Boric acid 2.5 g/L
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Protocol:
- Transformation of E. coli ER2566 with expression vector for
protein to be expressed
- Overnight culture, 20 mL of LB-medium with 1 % Glucose and 100
ng/mL Ampicillin
- Dilution with 800 mL of LB-medium with 100 ng/L Ampicillin
- Growth at 37 °C until OD600 reaches ~0.5 AU
- Induction with 0.5 mM IPTG and shift to 30 °C
- Incubation for 4 hours
- Centrifugation at 4000g
- Storage of bacterial pellets at –80 °C
6.3.3 Lysis of bacteria
Only too often incomplete lysis of bacteria is the one step where most of the
expressed protein is lost. Therefore careful complete lysis of bacteria is important.
Usually, bacteria are lysed by mechanical force either originating from the
shockwaves of collapsing bubbles induced by a high frequency sonicator, or from
shear forces during passage through a needle (or preferably from a French press).
Alternatively, lysis with chemical agents or enzymes can be useful but is limited to
at least remotely physiological conditions.
Reagents:
Buffer LA: 250 mM NaCl
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  50 mM HCO3
-/CO3
2- (pH 10.5)
  10 % Glycerol
   1 mM DTT
   1 mM PMSF
      Protease Inhibitors, EDTA free, complete (Roche)
6.3.4 Metal affinity chromatography
To ease the purification of recombinant proteins they are routinely tagged with
amino acid sequences that have a specific binding activity. The widely used
hexahistidine tag binds specifically and strongly to Ni (II) ions under various
conditions. For purification Ni (II) ions are coordinated by nitrilo acetic acid
(NTA), which in turn is covalently linked to agarose beads. This setup allows for
physical separation of recombinant hexahistidine tagged protein on an NTA-
agarose column. The column can be washed with buffer containing low
concentrations of imidazole and the bound protein eluted with high concentrations
of Imidazole or a more acidic pH.
Reagents:
Wash buffer: 200 mM NaCl
  20 mM Imidazole
  30 mM HCO3
-/CO3
2- (pH 10.5)
Elution buffer:  75 mM NaCl
200 mM Imidazole
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- Equilibration of Ni-NTA-Agarose (Qiagen, Hilden, Germany) with
10 column volumes of Buffer LA
- Loading of the column (gravity flow)
- Washing of the column with 30 column volumes of wash buffer
- Elution of the bound protein with 3 column volumes of elution
buffer
6.3.5 Anionexchange chromatography
In ionexchange chromatography a charged resin is employed to bind to charged
residues of proteins through electrostatic interaction. For anionexchange
chromatography it is ammonia groups (NH4
+) with a chloride counterion (Cl-).
Under low salt conditions negatively charged residues of proteins displace the
chloride ions and thus bind the protein to the resin. An increase in salt
concentration reverses this process eluting the protein again. Since the number and
arrangement of charged residues, which varies with individual proteins, determines
the strength of interaction, different proteins elute at different salt concentrations.
Reagents:
Equilibration buffer: 100 mM NaCl
  20 mM HCO3
-/CO3
2- (pH 10.5)
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Elution buffer      1 M    NaCl




- Equilibration of the column (HR 10/30, with resin SOURCE 15Q,
Amersham) with equilibration buffer
- Loading of the protein (eluate after metal affinity chromatography
in low salt buffer with 10 mM DTT, 50 µM ZnCl2, 2 mM EGTA)
- Washing of the column until the OD280 of the flowthrough is at
background level again (~ 30 column volumes)
- Elution of the bound proteins with a linear salt gradient from 100
mM to 1 M NaCl.
6.3.6 Size-exclusion chromatography
In size-exclusion chromatography molecules are separated according to their
hydrodynamic (rotating molecule plus hydrate shell) radii. Separation occurs when
the molecules flows through the column bed, packed with porous beads. The size
of the pores allows molecules small enough to enter and excludes bigger
molecules, forcing them to flow around the beads. As a result, larger molecules
have a shorter path through the column allowing them to elute earlier, or, more
accurately, at a lower elution volume than smaller molecules, thus separating
molecules according to their apparent hydrodynamic size.
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Reagents:
SX buffer: 200 mM NaCl
20 mM NaH2PO4/Na2HPO4 (pH 7.8)
0.005 % NaN3
Protocol:
- Equilibration of the column (Superdex 75 26/60, Amersham) with
buffer SX
- Loading of the sample (maximum volume 10 mL)
6.3.7 Hydroxyl-apatite chromatography
Hydroxyl-apatite is a mineral that binds nonspecifically to charged molecules, it is
used routinely to bind proteins or DNA. The bound protein can be eluted with a
buffer containing high concentrations of phosphate. Here, hydroxy-apatite was
used to re-concentrate E7 protein after dilution and renaturation (see below).
Reagents:
Hydroxyl-apatite (BIORAD)
Elution buffer:150 mM NaCl
250 mM Na2HPO4/NaH2PO4 (pH 7.6)
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    1 mM DTT
Protocol:
- Take 0.5 grams of hydroxy apatite and suspend them in water
- Allow the hydroxy apatite to settle and discard the supernatant
- Pour the slurry into a small column
- Load the column with the protein (gravity flow, ~ 1 mL/min)
- Elute the protein with 2 to 3 column volumes of elution buffer
6.3.8 Dialysis
Dialysis uses semi-permeable membranes to allow the slow, gentle, diffusion
controlled exchange of buffers without a change in sample volume. The
membranes are manufactured from regenerated cellulose, usually, and
characterized by their pore size, which determines the maximum size of molecules
allowed to pass through.
6.3.9 Renaturation (for E7 only)
Protein that was prepared under denaturing conditions, needs to be renatured at
some point to allow functional or biophysical studies of the native protein.
Usually, proteins are renatured by slowly removing the denaturing agent. This can
be done slowly by dialysis or more rapidly by dilution. Since the E7 protein
agglomerates rapidly if renatured at high concentrations it was chosen to be
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renatured by diluting the solution containing E7 in 8M Urea by a factor of 400
with renaturation buffer (GR Buffer).
Reagents:
GR Buffer: 150 mM NaCl







Protein concentrations were determined using the Bradford Protein Assay
(BIORAD) according to the manufacturer’s recommendation using bovine serum
albumine as a standard and by measuring the OD280 of the protein solution. To
determine the protein concentration from the OD280 it is necessary to determine the
molar extinction coefficient of the protein of interest. The molar extinction
coefficient is a parameter derived from the sum of the known absorbances at 280
nm of the all amino acids present in the individual protein. Thus, only the
concentration of proteins whose amino acid sequence is known can be determined
from their OD280. The calculation of the molar extinction coefficient was done with
the PROTEAN software, part of the DNAstar software bundle.
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Molar extinction coefficients:
E7:   5960 M-1cm-1
E6: 20170 M-1cm-1
S-E6:  29700 M-1cm-1
6.3.11 Discontinuous sodium dodecyl sulphate polyacrylamide gel
electrophoresis
In 1970 Laemmli and his colleagues introduced an ingenious method for the
analysis and separation of proteins according to their size, which immediately
became a method ubiquitous in molecular biology labs worldwide (Laemmli,
1970). While separation of nucleic acids on agarose or polyacrylamide gels is
fairly straightforward, with every single base having a negative charge providing
propulsion in an electric field, the separation of proteins in an electric field is a bit
tricky since proteins are built from aminoacids that can be charged positively or
negatively or not at all. To overcome this and to have all proteins move in the same
direction in an electric field SDS is added to the protein solution. SDS is an ionic
detergent that binds to proteins with a ratio of about 10 molecules/amino acid, thus
providing 9-11 negative charges/amino acid while unfolding the protein at the
same time. To unfold the proteins completely they are heat-denatured and reduced
with ßME. As a result, the proteins can be separated according to their size.
Furthermore, to increase the resolution a discontinuous system is used with
different pH and ionic strength in the buffer and the gel, which itself consists of a
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‘stacking’ gel at pH 6.8 and a ‘separating’ gel at pH 8.8 following. Once an
electric field is applied the chloride ions in the sample and stacking gel form the
leading edge of a moving boundary, with the trailing edge composed of glycine
molecules (from the buffer). Between the leading and trailing edges of the moving
boundary is a zone of lower conductivity and steeper voltage gradient that sweeps
the proteins from the sample and deposits them on the surface of the separating
gel. There, at the higher pH of the separating gel glycine is deprotonated. The
resulting glycine anions migrate through the stacked proteins and travel through
the separating gel immediately behind the chloride ions. Freed from the moving
boundary, the SDS-protein complexes move through the separating gel in a zone of
uniform voltage and pH and are separated according to their size.
Reagents:
5x Sample Buffer: 10% w/v SDS
 10 mM ßME
20 % v/v glycerol
0.2 M Tris-HCl, pH 6.8
0.05% w/v bromophenolblue
1x Running Buffer: 25 mM Tris-HCl
200 mM Glycine
0.1% (w/v) SDS
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Separating Gel Solution:
7% 10% 12% 15%
H2O 15.3 mL 12.3 mL 10.2 mL 7.2 mL
1.5 M Tris/HCl pH 8.8 7.5 mL 7.5 mL 7.5 mL 7.5 mL
20% (w/v)  SDS 0 .15  mL 0 .15  mL 0 .15  mL 0.15
mL
Acrylamide/Bis-acrylamide
(30%/0.8% w/v) 6 .9  mL 9 .9  mL 12 .0  mL 15.0
mL
10% (w/v)  APS 0 .15  mL 0 .15  mL 0 .15  mL 0.15
mL
TEMED 0 .02  mL 0 .02  mL 0 .02  mL 0.02
mL
Stacking Gel Solution (4% Acrylamide):
H2O 3.075 mL
0.5 M Tris/HCl, pH 6.8 1.25 mL
20% (w/v) SDS 0.025 mL
Acrylamide/Bis-acrylamide
(30%/0.8% w/v) 0.67 mL
10% (w/v) APS 0.025 mL
TEMED 0.005 mL
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Protocol:
- Assemble the glass plates of the gel system and check for leaks
- Prepare the separating gel solution in the desired percentage, adding
the polymerization starter (TEMED) last
- Pour the gel and leave some space for the stacking gel
- Cover the surface of the gel with 2-propanol
- Once the gel has set remove the 2-propanol and prepare the stacking
gel solution
- Pour the stacking gel solution on top of the separating gel and insert
the gel comb
- Once the stacking gel has set remove the comb and transfer the gel
into the gel tank
- Fill the tank with 1x running buffer
- Mix the samples with loading buffer and denature them at 95 ˚C for
five minutes
- Load the samples
- Run the gel at a voltage below 200 V and a current below 30 mA
(per minigel) until the desired separation has occurred
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6.3.12 Zinc (II)-ion quantitation
6.3.12.1 TSQ-assay
To determine the amount of zinc(II)-ions bound by E6 and E7 the protein was
oxidized with hydrogen peroxide (H2O2), rendering the respective amino acid
residues unable to coordinate zinc. The amount of ‘ejected’ zinc was then
determined by measuring the fluorescence of a complex of zinc and the fluorescent
indicator N-(6-methoxy-8-quinolyl)-p-toluene-sulfonamide (TSQ [Molecular
Probes, USA]) at 465 nm (excitation wavelength: 360 nm). Samples were
measured in triplicates and zinc concentrations calculated relative to external zinc
standards. The amounts determined were usually below 100 picomoles. The
standard errors, combined with an average error of 10 % for determination of
protein concentration (see: protein quantitation) were between 11 % and 24 %, as
indicated.
Reagents:
Buffer T: 10 mM Na2HPO4/NaH2PO4 (pH 7.0)
10 % Glycerol
Buffer TS: Buffer T + 200 µM TSQ (freshly added)
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TSQ Stock solution: 2.5 mM in DMSO (stored at –20 ˚C)
Protocol:
- 1-20 mL of protein solution were mixed with 5 mL H2O2 and Buffer
T to a final volume of 100ml on a 96-well plate. On the same plate
zinc standards for 0, 10, 20, 50 and 100 picomoles ZnCl2 were
prepared.
- Incubation at 25 °C for 30 minutes.
- Addition of 100 mL of Buffer TS
- Measurement of fluorescence at 460 nm (Excitation wavelength
365 nm)
6.3.12.2 Determination of zinc content by Inductively Coupled Plasma/Optical
Emission Spectroscopy (ICP/OES)
For validation of the zinc concentrations obtained with the fluorescence based TSQ
assay, purified, monomeric S-E6 protein was measured for its zinc content by
ICP/OES. In this method the liquid sample is nebulised into a plasma of
sufficiently high temperature to transform elements present into the gaseous
atomic state. In this state, the excited atoms emit at a characteristic wavelength
with an intensity proportional to their concentration. The spectroscope was
calibrated with standards at 0.1, 0.5, 1 and 2 ppm ZnCl2, respectively (BDH, UK).
Sample: 10 mL of a 0.16 mg/mL solution of monomeric S-E6 (after dialysis in the
presence of EGTA and size-exclusion chromatography).
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6.4 Protein-protein interaction assay with GST- “micro-columns”
The GST-pull-down assay is commonly used to investigate protein-protein
interactions in vitro. One of the interacting proteins is expressed in bacteria with a
GST-tag, while the suspected interaction partner is expressed in vitro, labeled with
35S-Methionine for easy detection via autoradiography.
Reagents:
NENT buffer: 100 mM NaCl
1 mM EDTA
0.5% NP-40
20 mM Tris-HCl (pH 8.0)
Glutathione sepharose beads Amersham Pharmacia Biotech, USA
Pull-down binding buffer: 50 mM KCl
40 mM HEPES (pH 7.5)
0.1% Tween 20
Protocol:
- Bind GST-fusion protein (approx. 100 µg) to glutathione sepharose
beads by adding 50 µL of a 1:1 slurry of glutathione sepharose
beads (equilibrated in NENT buffer) and NENT buffer to the
bacterial lysate (final volume 1 mL)
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- Centrifuge briefly (10 s) to check for equal amounts of beads in the
individual tubes.
- Mix samples at 4°C for 30 - 60 minutes in a tumbler.
- Centrifuge briefly and remove the supernatant carefully.
- Wash the beads twice with 0.5 - 1 mL cold NENT, spin briefly and
remove supernatant.
- Resuspend the beads in 200 µL NENT and fill the slurry into a
yellow pipette tip, partially blocked with a glass bead of 1.5-2 mm
in diameter (BDH). Assure beforehand that the blockage is not
complete, resulting in excruciatingly slow flow. Place the “column”
tip into a 1.5 mL tube on ice.
- Take 40 µL of a 50 µL in vitro translation reaction and add 360 µL
of "pull-down Binding Buffer" with 5 mM ß-mercaptoethanol and
0.5 % milk powder added freshly.
- Add the IVT target protein in "pull-down Binding Buffer" to the
GST column, being careful not to introduce air bubbles.
- Remove and discard the flow-through from the 1.5 mL tube before
washing the column twice with 200 µL of pull-down Binding
Buffer with 150 mM KCl.
- Remove the "micro-columns" from the 1.5 mL tube and, using a
scalpel blade, cut off the tip below the glass bead.
- Transfer the shortened column into a fresh 1.5 mL tube and add 30
µL SDS sample buffer to the column. Spin the tube briefly to force
the sample buffer into the column.
- Heat the tube to 95 °C for 5 min.
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- Add 30 µL of water to the column and spin for 10 seconds full-
speed in a microcentrifuge to elute the samples. Remove the column
from the Eppendorf tube.
- Run 20 µL of the sample on SDS PAGE.
- Stain gel with Coomassie blue, destain, enhance with Enlightening
TM (Du Pont, NEN Research Products) for 10 min.
- Dry the gel and expose X-ray film to it.
6.5 in vitro p53 degradation assay
35S-methionine labeled p53 was expressed using the TnT-Quick coupled
transcription/translation system (Promega, USA) according to the manufacturer’s
recommendation and incubated with 5nmoles purified S-E6 protein or buffer
without S-E6 (control) and ribonuclease A (to suppress further expression of p53)
at 30°C. Samples were taken at the time-points indicated and the reaction stopped
with sodium-dodecyl-sulphate (SDS) - loading buffer. The samples were run under
reducing conditions on SDS-polyacrylamide gels (SDS-PAGE) (Laemmli, 1970),
the gels dried and the resulting bands after autoradiography integrated using the
BIORAD Densitometer Software.
6.6 in vivo p53 degradation assay
U2-OS cells were transfected with 0.1 µg of a p53 expression vector and 1 µg of
different E6-expressing vectors; 24 h after transfection, cells were shifted to
medium containing 25 µg of cycloheximide per ml. Cells were harvested 0, 1, and
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3 h after cycloheximide treatment and lysed. Cell lysates were subjected to SDS-
PAGE (Laemmli, 1970) and analyzed by Western blotting using the anti-p53
antibody DO-1 (Santa Cruz, CA, USA).
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